Page last updated: 2024-09-05

lenalidomide and Disease Exacerbation

lenalidomide has been researched along with Disease Exacerbation in 191 studies

Research

Studies (191)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	24 (12.57)	29.6817
2010's	143 (74.87)	24.3611
2020's	24 (12.57)	2.80

Authors

Authors	Studies
Kunacheewa, C; Manasanch, EE	2
Ansell, SM; Desai, SH; Habermann, TM; Inwards, DJ; Johnston, PB; King, RL; LaPlant, B; Macon, WR; Micallef, I; Nowakowski, GS; Porrata, LF; Wang, Y; Witzig, TE	1
Casulo, C; Wallace, D	1
Akinyemi, O; Ali, A; Araoye, MO; Asemota, J; Ojo, AS; Ojukwu, SG; Saleh, M; Sarma, R	1
Certan, M; Garcia Garrido, HM; Goorhuis, A; Grobusch, MP; Heijmans, J; Wong, G	1
Agha, ME; Alsina, M; Anderson, KC; Anderson, LD; Andreescu, AC; Attal, M; Avet-Loiseau, H; Campagnaro, EL; Cohen, AD; Cornell, RF; Foley, A; Fulciniti, M; Gasparetto, C; Gentile, T; Ghobrial, IM; Giralt, SA; Godby, KN; Gowin, K; Hashmi, H; Hassoun, H; Hebert, K; Hurd, DD; Jacobus, SJ; Jagannath, S; Kamble, RT; Kaufman, JL; Khan, AM; Laubach, JP; Libby, EN; Liedtke, M; Lonial, S; Maglio, ME; Masone, K; McCarthy, PL; Medvedova, E; Milner, CP; Moreau, P; Munshi, NC; Nadeem, O; Nathwani, N; Openshaw, TH; Orlowski, RZ; Paba-Prada, C; Pasquini, MC; Perrot, A; Raje, NS; Richardson, PG; Samur, MK; Schlossman, RL; Scott, E; Torka, P; Voorhees, PM; Weller, EA; Yee, AJ; Zeytoonjian, AA; Zonder, JA	1
Fu, AZ; Kaila, S; Medhekar, R; Patel, S; Ran, T	1
Kumar, S; Lonial, S; Mateos, MV; Rajkumar, SV	1
Aguet, F; Anand, S; Aranha, MP; Badros, AZ; Baginska, J; Bhutani, M; Boruchov, A; Bustoros, M; Dutta, AK; Flechon, L; Getz, G; Ghobrial, IM; Hallisey, M; Haradhvala, NJ; Heilpern-Mallory, D; Jakubowiak, A; Laubach, J; Lightbody, ED; Manier, S; Mateos, MV; Matous, J; Mouhieddine, TH; Nadeem, O; Redd, RA; Richardson, P; Rosenblatt, JM; Savell, A; Sklavenitis-Pistofidis, R; Su, NK; Tahri, S; Trippa, L; Ujwary, S; Usmani, SZ; Varmeh, S; Vredenburgh, JJ; Wu, T; Yee, AJ; Zavidij, O; Zonder, J	1
Barwick, BG; Bernal, L; Boise, LH; Chen, Z; Dhodapkar, MV; Goyal, S; Gupta, VA; Heffner, LT; Hofmeister, CC; Jaye, DL; Joseph, N; Kaufman, JL; Lonial, S; Nooka, AK; Schmidt, TM; Wu, J	1
Gunji, T; Katori, M; Masuoka, H; Nishiwaki, K; Suzuki, K; Yano, S	1
Palazzo, G	1
Biran, N; Donato, ML; Goldberg, S; Ip, A; Kaur, G; Siegel, DS; Vesole, DH	1
Kocoglu, M; Li, A; Nageshwar, M; Sanchez-Petitto, G; Singh, Z; Tkaczuk, KHR	1
Menssen, AJ; Walter, MJ	1
Alici, E; Gran, C; Ljunggren, HG; Nahi, H; Susek, KH	1
Aasen, T; Abdul Moin, NI; Abdul Wafi, S; Aboukameel, A; Abu-Bakar, N; Acharya, A; Ackermans, L; Adaramoye, O; Adarsh, KV; Adeosun, WA; Ahmad, NH; Ahmadi, F; Akanni, O; Akbar, M; Akbulak, RO; Akev, N; Akkaya, Ö; Al-Rashed, S; AlAbbad, S; Alabi, O; Alappat, BJ; Alcalá, S; Alcoutlabi, M; Aleppo, G; Alexander Ross, JB; Alexander, JH; Alexander, R; Alias, A; Alimba, C; Alken, FA; Allan, R; Alpers, M; Alsbou, EM; Amarasiri, SS; An, T; Anastasiadis, F; Anastassiadou, M; Anderson, KC; Andronikos, P; Anheyer, D; Annapurna, K; Anorlu, RI; Anten, MM; Anthopoulos, TD; Araujo-Castillo, RV; Aravamudhan, S; Arawwawala, LDAM; Arulsamy, N; Arunamata, A; Asghar, A; Asiri, AM; Aslanidou, T; Astrakhantseva, IV; Astutik, E; Attanayake, AP; Atwater, BD; Audureau, E; Augusto, S; Bakare, A; Banach, M; Bandelier, P; Banerjee, S; Barral, M; Bascuñán, J; Bates, FS; Bauer, NJC; Bayrak, BB; Beck, RW; Beckervordersantforth, J; Beeri, R; Begum, R; Beldi-Ferchiou, A; Bellingham, G; Ben-Tal, N; Bendib, I; Bergenstal, RM; Berger, MF; Bernasconi, G; Berry, S; Beuvon, F; Bi, WJ; Bi, Z; Bianconi, V; Bibi, I; Blank, BR; Bliemeister, E; Bobkowski, W; Bode, AM; Booth, CM; Bose, U; Boyd, K; Brancato, A; Brenmoehl, J; Brogi, E; Bronzo, P; Brooks, T; Brown, D; Brown, DN; Bruce, D; Buan, MEM; Bueno-Hernández, F; Bugielski, B; Bulavaitė, A; Buscagan, TM; Buxton, R; Caffaro, MM; Cai, Q; Cai, X; Cai, Y; Calhoun, P; Callander, N; Cambier, S; Camparo, P; Canales-Vargas, EJ; Canham, K; Cantu, J; Cao, J; Cao, JW; Cao, P; Cao, T; Cao, X; Caravella, BA; Carcadea, E; Carè, J; Carmichael, P; Carrasco Cabrera, L; Carteaux, G; Carvalho, PDS; Casarez, E; Cazorla, M; Celestrin, CP; Chakraborty, NK; Chan, B; Chandarlapaty, S; Chandgude, AL; Chang, CC; Chang, JH; Chang, X; Chang, Y; Chankhanittha, T; Chantanis, S; Chapovetsky, A; Chavan, S; Chen, B; Chen, D; Chen, F; Chen, G; Chen, H; Chen, J; Chen, K; Chen, KJ; Chen, KP; Chen, L; Chen, MA; Chen, Q; Chen, S; Chen, W; Chen, WF; Chen, X; Chen, Y; Cheng, D; Cheng, J; Cheng, Q; Cheon, GJ; Chiu, SC; Cho, CH; Cho, J; Choi, H; Choi, JS; Choi, YH; Christie, P; Chu, CH; Chu, Y; Chung, DH; Chung, F; Cline, JP; Cohen, A; Cohen, AD; Cohen, NJ; Comen, E; Compter, I; Cong, J; Cong, Z; Cooper, A; Cornud, F; Costa, C; Costa, S; Covey, A; Cowan, AM; Cramer, H; Cruz-Rivera, C; Cui, J; Cui, M; Cui, Y; Cui, YH; Culquichicón, C; Cushman, T; D'Auria, SJ; da Silva, J; Dalgediene, I; Danenberg, HD; Das, S; Dasgupta, K; Daubit, IM; de Oliveira, PD; de Prost, N; De Ruysscher, D; Dearman, K; Decato, D; Delfau-Larue, MH; Deng, L; Dhakate, SR; Dharuman, V; Di Costanzo, N; Dickler, MN; Dinehart, EE; Ding, D; Dinh, TK; Divya, KP; Djifack Tadongfack, T; Do, T; Domínguez-Roldan, R; Domínguez-Zambrano, E; Dömling, A; Donato, MD; Dong, JH; Dong, W; Dong, X; Dong, XR; Dong, Y; Dong, Z; Downs, M; Drutskaya, MS; Du, B; Du, F; Du, H; Du, L; Du, X; Duan, Z; Duangthip, D; Dunstand-Guzmán, E; Duong, F; Eckert, DJ; Edelhäuser, BAH; Eekers, DBP; Efendi, F; Efraimidis, P; Ehrenberg, H; Ehsanbakhsh, Z; Eickholt, C; Eksterowicz, J; El Mobadder, M; El-Araby, IE; El-Magd, MA; El-Tarabany, MS; Elgorban, AM; Engelmann, D; English, KL; Esfandiari, H; Eslami, B; Espinosa-Cuevas, A; Eswara, S; Faber, E; Fan, XH; Fan, Y; Fang, J; Fang, Z; Fantin, VR; Fei, P; Feng, G; Feng, H; Feng, J; Feng, X; Feng, XJ; Fennell, TR; Fernández-Moreira, V; Ferraz, ABF; Ferreras, KN; Flores, K; Flores-Pérez, I; Flox, C; Fluharty, FL; Fokouong Tchoffo, E; Folefack, GO; Foroutan, T; Fort, D; Fourati, S; Fousas, S; Frapard, T; Freguia, S; Friedman, DJ; Friedman, LS; Fu, D; Fu, Q; Fu, Y; Fujinami, S; Furihata, K; Gal, RL; Gan, H; Gao, C; Gao, F; Gao, R; Gao, SS; Gao, W; Gao, XC; Gao, Y; Gao, Z; Garozi, L; Ge, J; Georgiopoulos, A; Gerakiou, K; Ghazimirsaeed, SM; Ghazimirsaeed, ST; Gimeno, MC; Gjestad, R; Glurich, I; Goetchius, E; Goland, S; Goldstein, S; Gonçalves, CM; Gonçalves, H; Gong, Q; Gonzalez, D; Goplen, FK; Gorshkova, EN; Gotsman, I; Govindasamy, V; Granger, CB; Greco, L; Grigoriadou-Skouta, E; Grigoropoulos, P; Grivicich, I; Gromov, NV; Gruber, S; Grytczuk, M; Grzech-Leśniak, K; Gu, L; Gu, S; Gu, Z; Guadagnini, D; Guan, H; Guilliams, M; Guo, J; Guo, L; Gupta, A; Gupta, SK; Gurzu, S; Gutleb, AC; Haban, A; Hablitz, JJ; Hadisuyatmana, S; Hahn, S; Haiges, R; Hallal-Calleros, C; Hamed, M; Hammad, N; Hammer, N; Han, C; Hao, Y; Harnett, J; Has, EMM; Hassanpour, K; Hatzopoulos, D; Hawaldar, R; He, X; He, Y; He, YY; He, Z; Heberman, D; Heckl, D; Hegde, H; Henson, MA; Hernández-Velázquez, VM; Herrera, E; Hijazi, Z; Hirayama, K; Hirth, JM; Hoeben, A; Hohnloser, SH; Hong, M; Hood, K; Hoplock, LB; Hopman, WM; Horlbogen, LM; Hossein Rashidi, B; Hou, G; Hou, H; Hou, J; Hou, Y; Hu, J; Hu, W; Hu, X; Hua, W; Huang, G; Huang, H; Huang, J; Huang, T; Huang, W; Huang, Y; Huang, YD; Huang, Z; Hudis, CA; Hue, S; Huo, J; Hussain, M; Hvas, AM; Ichii, T; Ide Zeuna, J; Ilyas, S; Inoue, T; Iranzo, A; Irfan, M; Iwasa, Y; Iwashita, Y; Izgorodina, EI; J R, A; Jaber, WA; Jaborek, JR; Jacobus, SJ; Jadeja, SD; Jafarabadi, M; Jalan, D; Jamil, MI; Jarrah, S; Jarvis, D; Jayatilaka, KAPW; Jemal-Turki, A; Jeon, YK; Jeong, N; Jeong, SH; Jeong, SY; Jermy, M; Jhaveri, K; Ji, H; Ji, K; Ji, RY; Jiang, F; Jiang, J; Jiang, X; Jiang, Y; Jiao, Q; Jilani, K; Jiménez-Guerrero, P; Jin, L; Jo, YH; Johnson, JG; Johnson, ML; Jones, WS; Jose, S; Jularic, M; Jung, I; Jung, YJ; Jungen, C; Junttila, MR; Kache, S; Kahanovitch, U; Kalantzi, KI; Kallio, T; Kamnoedboon, P; Kang, CH; Kang, H; Kang, J; Kang, KW; Kapoor, P; Karmakar, D; Kartalis, A; Kauranen, P; Kazocina, A; Keikha, F; Keltai, M; Kershaw, SV; Kettani, M; Khalvati, S; Khandhar, S; Khosla, N; Kiely, CJ; Kim, CC; Kim, H; Kim, MJ; Kim, Y; Kim, YH; Kim, YT; Kimoto, E; Kiyu, A; Klatt, N; Kobayashi, M; Koh, J; Köhler, R; Kondadasula, SV; Kong, H; Kong, W; Kong, X; Kotidis, A; Kotwal, A; Kouvari, M; Kozhinov, AN; Kruger, D; Kuang, S; Kuang, Y; Kubota, M; Kuklik, P; Kumar, P; Kumar, SK; Kuo, YF; Kurup, SP; Kusuhara, H; Kuswanto, H; Lacouture, ME; Lambin, P; Lang, CC; Langroudi, FH; Lanman, RB; Larsen, OH; Laskin, J; Le, VH; Leach, M; Lee, BG; Lee, DF; Lee, DS; Lee, HJ; Lee, SB; Lee, YA; Lei, Y; Lekashvili, O; Lelj, F; Lemin, AS; Lemoine, J; Leuschner, R; Li, B; Li, BT; Li, C; Li, D; Li, F; Li, G; Li, H; Li, HW; Li, J; Li, M; Li, P; Li, Q; Li, S; Li, W; Li, X; Li, XY; Li, Y; Li, Z; Lian, Y; Liang, C; Liao, J; Liao, W; Liao, Y; Lin, D; Lin, W; Lin, YL; Lindbäck, J; Lindsay, AP; Ling, J; Linser, PJ; Liu, C; Liu, H; Liu, JJ; Liu, L; Liu, Q; Liu, SF; Liu, X; Liu, Y; Liu, Z; Liu, ZM; Lo Sterzo, C; Lo, ECM; Lobchuk, MM; Lodge, TP; Logotheti, S; Lonial, S; Lopes, G; Lopes, RD; Lopez, J; Lopez, SA; López-Santos, AL; López-Sendón, JL; Loring, Z; Louis, C; Lovita, AND; Lu, DZ; Lu, H; Lu, J; Lu, K; Lu, TT; Lu, Y; Luengo, A; Lum, LG; Luna, JM; Luo, L; Luo, R; Luo, T; Luo, X; Luo, Z; Lv, B; Lymperopoulos, N; Lyras, A; Lyu, Y; M Kannan, A; Ma, H; Ma, M; Ma, Q; Ma, S; Ma, WY; Ma, Y; Maalouf, E; Machado, FA; Maeda, K; Magrans, JO; Maharani, A; Maia, G; Mainwaring, RD; Maji, TK; Majumdar, K; Mannarino, MR; Mansuri, MS; Marinescu, SC; Markatos, G; Marquardt, S; Marraiki, N; Martens, C; Martínez, TJ; Marumo, K; Maruyama, H; Marwani, HM; Marzo, I; Masrati, G; Matamba, P; Mathialagan, S; Matys, J; Mayatra, JM; Mboua, PC; McArthur, T; McCrimmon, RJ; McIntosh, S; McSpadden, S; Medina-Campos, ON; Medvedovsky, AT; Mei, Z; Mekontso-Dessap, A; Menezes, AMB; Meng, J; Meng, P; Meng, Y; Menter, A; Mets, MB; Mets-Halgrimson, R; Metzger, T; Metzler-Nolte, N; Meyer, C; Mi, Y; Michailoviene, V; Mikrogeorgiou, A; Militz, H; Miller Iii, TF; Minarowska, A; Mir, S; Miron, I; Miyake, T; Moayer, F; Modi, S; Moeller, SJ; Mohamad, MN; Mohammed, EHM; Mokhonov, VV; Mondal, A; Moore, J; Moravcova, M; Mordi, IR; Mordi, NA; Mortensen, NP; Moscariello, C; Moser, J; Moynahan, ME; Mu, J; Mu, W; Mudduwa, LKB; Mukherjee, S; Mukhtar, A; Mulkey, DK; Murr, N; Mushtaq, Z; Muthuswamy, N; Mutlu, O; Muto, C; Myroforou, I; Na, KJ; Nabi, M; Nagornov, KO; Nagy, RJ; Naik, A; Nakajima, K; Nam, KT; Nam, YW; Namburath, M; Nammour, S; Namour, A; Namour, M; Nanan, S; Natsume, H; Nave, S; Naveed, A; Nazir, H; Ndubaku, C; Nedospasov, SA; Neradilek, MB; Newcomb, C; Nguépy Keubo, FR; Nguyen, M; Ning, J; Ning, Q; Noguchi, S; Nordahl, SHG; Nordfalk, KF; Norton, L; Noupoue, EM; Nouri, SS; Nowak, JK; Núñez, K; Oakes, K; Odegaard, JI; Ogorodnikova, OL; Ogunsuyi, O; Oh, HK; Oh, HR; Oh, KH; Ohgi, K; Okunade, KS; Oliveira, AG; Olorunfemi, G; Olsen, ML; Olson, BA; Omari, KW; Ondruschka, B; Orfali, R; Orkopoulos, A; Orlowski, RZ; Oser, SM; Oser, TK; Özcan, M; Padilla, V; Paeng, JC; Pajuelo-Lozano, N; Pal, SK; Palmieri, S; Palomeque, E; Pan, W; Panagiotakos, DB; Pandey, M; Pang, D; Pang, Q; Pangarah, CA; Panny, A; Paparella, A; Papirio, S; Papouskova, K; Parang, K; Park, HJ; Park, IK; Park, S; Parker, TL; Parkhomenko, A; Parmon, VN; Parsons, B; Parsons, J; Patel, PR; Patil, S; Patsourakos, NG; Patterson, KC; Pavlidis, P; Pedernera, M; Pedersen, R; Pedraza-Chaverri, J; Pellegrini, M; Peña-Chora, G; Pereira, EDM; Pereira, MADS; Peretz, A; Perez-Padilla, R; Perlman, GY; Perona, R; Petras, C; Phuntsho, S; Picada, JN; Pinder, TA; Piper, LFJ; Pirozzi, F; Pirro, M; Pleckaityte, M; Ploutz-Snyder, LL; Ploutz-Snyder, R; Pogorzelski, A; Poles, L; Postma, AA; Prager, A; Prakash, J; Punn, R; Pützer, BM; Qi, J; Qi, MC; Qi, Y; Qian, J; Qian, Y; Qiang, L; Qiu, J; Qu, Y; Rabiu, KA; Rahighi, S; Rahman, MM; Rahmani, B; Rajkumar, SV; Ramanathan, R; Raras, TYM; Rashi, Y; Rasool, G; Rathore, MG; Ratnawati, R; Ratola, N; Raucci, U; Ray, SK; Razavi, P; Razazi, K; Razek, S; Razi, SS; Reback, M; Reddy, K; Rees, DC; Reginatto, FH; Reich, H; Reis-Filho, JS; Ren, X; Ren, Y; Renner, G; Rey, G; Reymen, B; Riaz, M; Ricci, A; Richardson, PG; Richter, C; Riga, M; Ritchie, C; Rivoal, S; Roberts, W; Robson, ME; Rocha, GZ; Rodrigues, AD; Rogach, AL; Rojas, A; Rosenberg, A; Rosenberg, E; Rosenheck, RA; Roslan, K; Rothenberger, C; Rouschop, KMA; Rubagumya, F; Ryan, CM; Ryder, JW; Saad, MJA; Sacan, O; Sacchi, A; Sahebkar, A; Saini, A; Sainz, B; Sajo, EA; Sakizadeh, J; Saleh, AA; Salgado Júnior, IB; Salvi, R; Samoylova, YV; Samuni, A; Sanchez, DM; Sanchez-Perez, I; Santos, M; Sarapulova, A; Sardot, T; Saud, N; Sauerbier, P; Scaltriti, M; Schaeffer, B; Schalk, DL; Scherschel, K; Schijven, MP; Schreuder, HWR; Schuhmacher, M; Schultz-Lebahn, A; Schwarzl, J; Scott, JM; Sebayang, SK; Seeger, ZL; Segabinazi Peserico, C; Selenica, P; Serio, A; Seruga, B; Shah, A; Shah, C; Shah, PD; Shahrokh Tehraninezhad, E; Shan, A; Shao, Z; Sharma, AMR; Sharma, RK; Shen, J; Shen, R; Shi, X; Shi, Y; Shi, ZE; Shih, YC; Shimohata, H; Shimpi, N; Shin, SH; Shon, HK; Shuvy, M; Siddique, AB; Siegbahn, A; Sikandar, M; Silvani, Y; Singh, A; Singh, AK; Singh, D; Singh, JS; Singh, KP; Singh, M; Situ, B; Skipper, MT; Skouloudi, M; Sloane, BF; Smyrnioudis, N; Snyder, MA; Söhnchen, C; Solis Condor, R; Solit, DB; Someya, S; Song, H; Song, J; Song, W; Song, Y; Sorokina, KN; Soshi, S; Soyer, P; Spitschak, A; Sreekrishnan, TR; Srinivasan, M; Staruschenko, A; Steel, A; Stefan-van Staden, RI; Stein, AM; Strayer, H; Struthers, AD; Su, H; Su, Q; Su, X; Sudore, RL; Sugimura, H; Sugiyama, Y; Sujuti, H; Sumner, SJ; Sun, B; Sun, D; Sun, H; Sun, J; Sun, JY; Sun, X; Sun, Y; Sun, Z; Sung, YC; Surenaud, M; Sutimantanapi, D; Suwandaratne, NS; Swaroop, S; Sychrova, H; Syed, A; Szczepanik, M; Szederjesi, J; Szodorai, R; Tacy, TA; Tadelle, RM; Takayasu, M; Tammeveski, K; Tan, H; Tan, M; Tang, HX; Tang, S; Tang, X; Tanokura, M; Tao, F; Tao, H; Tarafdari, A; Tarín-Carrasco, P; Tasson Tatang, C; Teixeira, JP; Thakur, A; Theobald, A; Thevenot, P; Thomaidis, K; Tian, J; Tillib, SV; Toma, C; Tomita, M; Tonchev, I; Tong, F; Toy, W; Trypuć, M; Tselepis, AD; Tsetseris, L; Tsikouri, GE; Tsikouris, EI; Tsoplifack, CB; Tsoumani, ME; Tsujimoto, R; Tsybin, YO; Tu, J; Tu, TM; Turco, M; Turkyilmaz, IB; Uddin, MJ; Ung, J; Unsihuay, D; Utsunomiya, T; Vagenende, B; Vaishnav, J; Valdes, C; Validad, MH; Valle, J; van Ginkel, MPH; van Grevenstein, WMU; Vanderpuye, V; Vasan, N; Vasilenko, EA; Vasques, GJ; Vavoulis, P; Verani, A; Veziroglu, E; Viegas, A; Vitali, MG; Vitsas, G; Voccio, JP; Vogiatzidis, C; Volow, A; Volpin, F; Vourvahis, M; Wagner, LI; Walkowiak, J; Wallace, R; Wallentin, L; Wan, D; Wan, L; Wan, T; Wang, C; Wang, F; Wang, FN; Wang, H; Wang, J; Wang, L; Wang, Q; Wang, S; Wang, T; Wang, W; Wang, X; Wang, XW; Wang, Y; Wang, YS; Wang, Z; Ward, J; Ward, L; Waseem, R; Watson, DF; Weber, P; Wehrmeister, FC; Wei, CH; Wei, H; Wei, L; Wei, Q; Wei, Y; Weinstock, RS; Weiss, M; Welborn, M; Wen, L; Wen, LM; Wen, Q; Wen, Z; Wesseling, P; Westerbergh, J; White, K; Wick, MP; Willems, S; Wiyasa, IWA; Wójciak, R; Wolkenhauer, O; Won, HH; Wong, J; Woo, YC; Wood, LS; Wu, CT; Wu, CY; Wu, D; Wu, G; Wu, J; Wu, K; Wu, M; Wu, Q; Wu, T; Wu, W; Wu, X; Wu, XT; Wu, Y; Xi, D; Xi, J; Xiang, W; Xiang, Y; Xiao, M; Xiao, Z; Xie, H; Xie, Q; Xie, S; Xie, X; Xing, M; Xing, YL; Xu, C; Xu, X; Xu, Y; Xu, Z; Xue, F; Xue, XD; Yaglioglu, HG; Yamada, H; Yamashita, M; Yan, W; Yan, Z; Yanardag, R; Yang, D; Yang, H; Yang, K; Yang, QQ; Yang, R; Yang, S; Yang, T; Yang, X; Yang, Y; Yao, H; Yao, Y; Yari, D; Yassin, MT; Ye, C; Ye, J; Ye, Q; Yildiz, EA; Ying, S; Yoon, H; Yu, D; Yu, K; Yu, N; Yu, PL; Yuan, C; Yuan, D; Yuan, LJ; Yuan, Z; Yuen, N; Zagatto, AM; Zakaria, Y; Zalewski, AM; Zamora, S; Zavorotinskaya, T; Zeid, JL; Zeinoun, T; Zeng, C; Zerby, HN; Zhan, X; Zhang, A; Zhang, D; Zhang, E; Zhang, F; Zhang, H; Zhang, J; Zhang, L; Zhang, M; Zhang, P; Zhang, Q; Zhang, QY; Zhang, RG; Zhang, S; Zhang, T; Zhang, X; Zhang, Y; Zhang, YY; Zhao, CK; Zhao, H; Zhao, J; Zhao, K; Zhao, Q; Zhao, S; Zhao, T; Zhao, XQ; Zhao, Y; Zhao, Z; Zheng, J; Zheng, L; Zheng, Y; Zhou, B; Zhou, G; Zhou, L; Zhou, T; Zhou, X; Zhu, C; Zhu, J; Zhu, Y; Zhu, ZQ; Zhuang, T; Zimmermannova, O; Zin, NNINM; Zisimos, K; Zoghebi, KA; Zonder, JA; Zou, C; Zwirner, J	1
Karsan, A; Martinez-Høyer, S	1
Anderson, K; Bahlis, N; Belch, A; Brown, D; Chen, C; Cheung, M; Dispenzieri, A; Facon, T; Robinson, S; Shustik, C; Song, K; Srinivasan, S; Tosikyan, A; White, D	1
Balleari, E; Campelo, MD; Fenaux, P; Germing, U; Götze, KS; Guerci-Bresler, A; Hamel, JF; Kelaidi, C; Komrokji, R; Kotsianidis, I; Park, S; Santini, V; Sanz, GF; Sekeres, MA; Stamatoullas, A; Steensma, D; Thépot, S; Toma, A	1
Goodman, AM; Kim, MS; Prasad, V	1
Bolaman, AZ; Eroğlu Küçükerdiler, H; Ertop, Ş; Sahip, B; Sargın, G; Selim, C; Turgutkaya, A; Yavaşoğlu, İ	1
Hou, HA; Liu, Y; Qiu, H; Siggins, S; Tang, CH	1
Döhner, K; Gabdoulline, R; Ganser, A; Ganster, C; Germing, U; Göhring, G; Gutermuth, A; Haase, D; Haferlach, C; Haferlach, T; Heuser, M; Kandziora, C; Klement, P; Klesse, S; Kobbe, G; Koenecke, C; Kröger, N; Krönke, J; Kubasch, AS; Meggendorfer, M; Mies, A; Panagiota, V; Platzbecker, U; Schiller, J; Schlegelberger, B; Schroeder, T; Shahswar, R; Shirneshan, K; Sperr, WR; Thiede, C; Thol, F; Valent, P	1
Balleari, E; Bernal, T; Beyne-Rauzy, O; Bordessoule, D; Calabuig, M; Cametti, G; Campelo, MD; Cheze, S; Cony-Makhoul, P; Dreyfus, F; Fenaux, P; Fensterl, J; Ferrero, D; Gaidano, G; Germing, U; Gioia, D; Götze, K; Guerci-Bresler, A; Hamel, JF; Kaivers, J; Kelaidi, C; Komrokji, R; Kotsianidis, I; Müller-Thomas, C; Pane, F; Park, S; Ramos, F; Roboz, GJ; Rose, C; Sanna, A; Santini, V; Sanz, GF; Sapena, R; Sekeres, MA; Stamatoullas, A; Steensma, DP; Thépot, S; Toma, A; Vey, N; Wattel, E	1
Becker, PS; Bensinger, W; Holmberg, LA	1
Blijlevens, NMA; Cermak, J; Chiba, K; da Silva-Coelho, P; de Graaf, AO; de Witte, T; Dugas, M; Huls, G; Jansen, JH; Knops, R; Koorenhof-Scheele, TN; Kroeze, LI; Massop, M; Miyano, S; Muus, P; Ogawa, S; Sandmann, S; Shiraishi, Y; Stevens-Kroef, MJ; Tanaka, H; van de Locht, LT; van der Reijden, BA; Yoshida, K	1
Bagot, M; Beylot-Barry, M; Chaby, G; Cowan, R; Dalle, S; Fox, CP; Hasan, B; Jonak, C; Knobler, R; Marreaud, S; Morris, S; Quaglino, P; Ritchie, D; Romero, PLO; Scarisbrick, J; Servitje, O; Shah, E; Stadler, R; Väkevä, L; Vermeer, MH; Whittaker, S	1
Cao, Z; Tian, C; Yang, H; Zhang, Q; Zhang, Y; Zhu, L	1
Beyne-Rauzy, O; Deeg, HJ; Del Cañizo, C; Fenaux, P; Giagounidis, A; Greenberg, PL; Guerci-Bresler, A; Hellström-Lindberg, E; List, AF; Mittelman, M; Muus, P; Nimer, SD; Powell, BL; Sekeres, MA; Selleslag, D; Shammo, JM; Skikne, B; Yu, X	1
Chen, WM; Fu, ZZ; Hu, Y; Huang, XJ; Huang, ZX; Jin, FY; Li, XL; Liao, AJ; Liu, H; Lu, J; Meng, FY; Wang, GM; Wang, XM; Yang, GZ; Zhang, X; Zhong, YP; Zhou, JF	1
Anderson, KC; Attal, M; Bringhen, S; Caillot, D; Gay, F; Holstein, SA; Hulin, C; Jung, SH; Knight, RD; Marit, G; McCarthy, PL; Moreau, P; Musto, P; Palumbo, A; Petrucci, MT; Richardson, PG; Tosi, P; Winograd, B; Yu, Z	1
Chen, Y; Fang, Y; Fei, XC; Janin, A; Jiang, XF; Leboeuf, C; Li, B; Song, Q; Sun, YF; Wang, CF; Wang, L; Xu, PP; Yan, ZX; Zhao, WL; Zhao, Y	1
Chen, BB; Cheng, AL; Hsu, C; Hsu, CH; Lin, ZZ; Ou, DL; Shao, YY; Wang, MJ	1
Bhatnagar, V; Farrell, AT; Goldberg, KB; Gormley, NJ; Luo, L; Ma, L; McKee, AE; Pazdur, R; Shen, G; Shen, YL; Shord, S; Sridhara, R; Subramaniam, S	1
Al-Sawaf, O; Aldaoud, A; Bahlo, J; Bosch, F; Böttcher, S; Döhner, H; Dörfel, S; Eichhorst, B; Fink, AM; Fischer, K; Ghia, P; Hallek, M; Hebart, H; Jentsch-Ullrich, K; Kater, AP; Kneba, M; Kreuzer, KA; Nösslinger, T; Ritgen, M; Robrecht, S; Stilgenbauer, S; Tausch, E; Wendtner, CM	1
Bergh, J; Camarero Jiménez, J; Demolis, P; Garcia, I; Gisselbrecht, C; Laane, E; Ludwig, H; Martin, M; Moreau, A; Pignatti, F; Salmonson, T; Sancho-López, A; Tzogani, K	1
Barnett, E; Bravo, MC; Ghosh, N; Goy, A; Hamadani, M; Lossos, IS; Martin, P; Phillips, T; Reeder, CB; Rule, S; Schuster, SJ; Wang, M	1
Ahlberg, L; Alici, E; Blimark, C; Carlsson, C; Forsberg, K; Gréen, H; Gruber, A; Hardling, M; Jakobsen Falk, I; Lauri, B; Lotfi, K; Lund, J; Mellqvist, UH; Nahi, H; Swedin, A	1
Béné, MC; Cartron, G; Commes-Maerten, T; Delaunay, J; Eveillard, M; Flet, L; Gagez, AL; Godmer, P; Godon, C; Le Bris, Y; Lodé, L; Loirat, M; Luycx, O; Ménard, A; Pellat-Deceunynck, C; Peterlin, P; Richebourg, S; Soussi, T; Theisen, O; Villemagne, B	1
Campioni, M; DeCosta, L; Fink, L; Flinois, A; Gazzola, C; Gonzalez-McQuire, S; Leleu, H; Mennini, FS; Schoen, P; Yong, K	1
Almeida, A; Altincatal, A; Beach, CL; Buckstein, R; Fenaux, P; Giagounidis, A; Guo, S; Platzbecker, U; Santini, V; Wu, C	1
Ebert, BL; Fenaux, P; List, A	1
Arcioni, F; Covezzoli, A; Cundari, S; Di Battista, V; Mecucci, C; Roncadori, A; Tura, S	1
Adamson, L; Eriksson, I; Gentilcore, G; Hansson, L; Heimersson, K; Mellstedt, H; Mozaffari, F; Mulder, TA; Näsman-Glaser, B; Österborg, A; Palma, M; Ryblom, H; Svensson, A	1
Aldaoud, A; Harde, J; Knauf, W; Losem, C; Mittermueller, J; Neise, M; Niemeier, B; Potthoff, K; Trarbach, T	1
Berg, D; Hari, P; Lin, HM; Moreau, P; Richardson, PG; Zhu, Y	1
Aceituno, S; Appierto, M; Gozalbo, I; Lizán, L	1
Abonour, R; Abouzaid, S; Durie, BGM; Gasparetto, CJ; Hardin, JW; Jagannath, S; Kitali, A; Narang, M; Parikh, K; Rifkin, RM; Srinivasan, S; Terebelo, HR; Toomey, K; Wagner, L; Zafar, F	1
Betts, KA; Brun, A; Chen, C; Dimopoulos, MA; Lonial, S; Makenbaeva, D; Mekan, S; Richardson, PG; Signorovitch, JE; Sy, O; Weisel, K; Zichlin, ML	1
Platzbecker, U; Sockel, K	1
Burgos, S; Fuente, L; Garcia-Manero, G; Jabbour, EJ; Kanagal-Shamanna, R; Mela-Osorio, MJ; Montalban-Bravo, G; Soltysiak, KA	1
Bashey, A; Blackwell, B; Brunstein, C; Devine, S; Efebera, Y; Ganguly, S; Gasparetto, C; Geller, N; Giralt, S; Hari, P; Horowitz, MM; Knust, K; Koreth, J; Krishnan, A; Landau, H; McCarthy, P; Nelson, C; Pasquini, MC; Qazilbash, MH; Shah, N; Somlo, G; Stadtmauer, EA; Vesole, DH; Vij, R; Vogl, DT	1
Platzbecker, U	1
Ando, K; Aoyama, Y; Kawada, H; Kitamura, Y; Nakamura, Y; Ogawa, Y; Suzuki, R; Warita, T	1
Du, H; Feng, Y; Fu, C; Weng, H; Yang, C; Zhang, L; Zhao, S; Zou, L	1
Alahmadi, M; Atenafu, EG; Chen, C; Kukreti, V; Masih-Khan, E; Reece, DE; Tiedemann, R; Trudel, S	1
Mateos, MV; Moreau, P; Zamagni, E	1
Abril, L; Clapés, V; Gassiot, S; González, Y; Ibarra, G; Maluquer, C; Morgades, M; Motlló, C; Oriol, A; Ribera, JM	1
Alati, C; Alimena, G; Aloe Spiriti, MA; Balleari, E; Breccia, M; Cortelezzi, A; D'Errigo, MG; Finelli, C; Galimberti, S; Laganà, C; Latagliata, R; Morabito, F; Nobile, F; Oliva, EN; Palumbo, G; Poloni, A; Rodà, F; Sanpaolo, G; Specchia, G; Volpe, A	1
Alsina, M; Bensinger, WI; Kunkel, LA; Lee, S; Martin, TG; Niesvizky, R; Orlowski, RZ; Siegel, DS; Wang, M; Wong, AF	1
Amraoui, K; Belhadj, K; Dupuis, J; Jannière-Nartey, C; Maître, B	1
Badillo, M; Bejarano, M; Champlin, R; Chen, Y; Cheng, N; Desai, M; Fanale, M; Fayad, L; Feng, L; Fowler, N; Hagemeister, F; Hosing, C; Kwak, L; Neelapu, SS; Newberry, KJ; Oki, Y; Pro, B; Romaguera, J; Shah, J; Thomas, S; Wagner-Bartak, N; Wang, M; Younes, A; Young, KH; Zhang, L	1
Alvarez, S; Arenillas, L; Calasanz, MJ; Cervera, J; Cigudosa, JC; Costa, D; Del Rey, M; Diez-Campelo, M; Florensa, L; González-Martínez, T; Hernández, JM; Ibáñez, M; Jerez, A; Larráyoz, MJ; Lumbreras, E; Maciejewski, J; Mallo, M; Marugán, I; Nomdedeu, M; Pedro, C; Solé, F; Such, E	1
Aoki, K; Arima, H; Imai, H; Ishikawa, T; Kato, A; Matsushita, A; Mori, M; Nagano, S; Ono, Y; Tabata, S; Takahashi, T; Takiuchi, Y; Yanagita, S	1
Bernasconi, P; Cazzola, M; Cocito, F; Corso, A; Mangiacavalli, S; Pochintesta, L; Pompa, A	1
Bosly, A; Coiffier, B; Delarue, R; Fitoussi, O; Gabarre, J; Glaisner, S; Haioun, C; Li, J; Lister, J; Morschhauser, F; Quach, H; Thieblemont, C	1
Boccadoro, M; Cavallo, F; Corradini, P; Crippa, C; Ferrari, S; Gay, F; Giuliani, N; Guglielmelli, T; Liberati, AM; Magarotto, V; Montefusco, V; Offidani, M; Oliva, S; Omedé, P; Palumbo, A; Passera, R; Patriarca, F; Pescosta, N; Petrucci, MT; Pezzatti, S; Pietrantuono, G	1
Ai, H; Cai, Z; Chen, F; Chen, N; Du, X; Hou, J; Jin, J; Ke, X; Li, X; Mei, J; Meng, F; Wang, J; Wortman-Vayn, H; Wu, D; Yu, L; Zhang, J; Zhou, DB	1
Czuczman, MS; Habermann, TM; Li, J; Lossos, IS; Pietronigro, D; Reeder, CB; Tuscano, JM; Vose, JM; Witzig, TE; Zinzani, PL	1
Brunet-Possenti, F; Crickx, B; Descamps, V; Hermine, O; Marinho, E	1
Bargay, J; Bladé, J; de Arriba, F; de la Rubia, J; García, JL; Giraldo, P; Hernández, MT; Lahuerta, JJ; López Corral, L; López, J; Mateos, MV; Olavarría, E; Oriol, A; Paiva, B; Palomera, L; Prosper, F; Quintana, N; Rosiñol, L; San Miguel, JF	1
Avet Loiseau, H; Bonnet, S; Debarri, H; Demarquette, H; Facon, T; Fouquet, G; Gay, J; Guidez, S; Herbaux, C; Hulin, C; Leleu, X; Michel, J; Miljkovic, D; Perrot, A; Serrier, C; Tardy, S	1
Cicero, S; Drach, J; Fu, T; Goy, A; Kalayoglu Besisik, S; Ramchandren, R; Sinha, R; Williams, ME; Witzig, TE; Zhang, L	1
Alsina, M; Bensinger, W; Huang, M; Kavalerchik, E; Martin, T; Niesvizky, R; Orlowski, RZ; Siegel, DS; Wang, M	1
Fenaux, P; Germing, U; Giagounidis, A; List, A; MacBeth, KJ; Mufti, GJ	1
Bennett, JM; Fu, T; Giagounidis, A; Knight, RD; List, AF; Nimer, SD; Sekeres, MA; Shammo, JM; Skikne, B	1
Kelby, SK; Lestingi, TM; Nabhan, C; Patel, A; Tolzien, K; Villines, D	1
Buadi, FK; Dingli, D; Dispenzieri, A; Gertz, MA; Go, R; Hayman, SR; Kapoor, P; Kourelis, TV; Kumar, SK; Kyle, RA; Lacy, MQ; Leung, N; Lin, Y; Lust, JA; Rajkumar, SV; Russell, SJ; Srivastava, G; Zeldenrust, SR	1
Ardanaz, MT; Arrizabalaga, B; Azaceta, G; Bargay, J; Cabrero, M; Calabuig, M; Cedena, T; Cerveró, C; Collado, R; del Cañizo, C; Díez-Campelo, M; García, M; Luño, E; Morell, MJ; Muñoz, JA; Nomdedeu, B; Pedro, C; Rodríguez, MJ; Rojas, SM; Simiele, A; Xicoy, B	1
Becker, PS; Bensinger, WI; Burwick, N; Green, DJ	1
Kuendgen, A	1
Tohyama, K	1
Arilla, MJ; Arrizabalaga, B; Azaceta, G; Bailén, A; Bargay, J; Brunet, S; Cerveró, C; de Paz, R; Del Cañizo, C; Diez-Campelo, M; Falantes, J; García-Pintos, M; Lorenzo, I; Luño, E; Marco-Betes, V; Nomdedeu, B; Osorio, S; Ramos, F; Sánchez-García, J; Sanz, GF; Serrano-López, J; Such, E; Tormo, M; Valcárcel, D; Xicoy, B	1
Choquet, S; Leblond, V; Nguyen, S; Souchet-Cömpain, L	1
Benettaib, B; Beyne-Rauzy, O; Bowen, D; del Cañizo, C; Fenaux, P; Fu, T; Ganser, A; Giagounidis, A; Göhring, G; Guerci-Bresler, A; Hellström-Lindberg, E; Lübbert, M; Mittelman, M; Mufti, GJ; Muus, P; Nilsson, L; Platzbecker, U; Quesnel, B; Sanz, G; Schlegelberger, B; Selleslag, D; te Boekhorst, P	1
Schleiffenbaum, BE	1
Chung, DJ; Devlin, S; Giralt, SA; Hassoun, H; Hilden, P; Koehne, G; Landau, H; Lendvai, N; Lesokhin, AM; Redling, K; Schaffer, WL; Tsakos, I	1
Hahn-Ast, C; Kanz, L; Oehrlein, K; Rendl, C; Weisel, K; Zago, M	1
Ali, SM; Chmielecki, J; Miller, VA; Morosini, D; Palmer, GA; Ross, JS; Sharman, JP; Stafl, J; Stephens, PJ	1
Cheng, J; Lamy, T; Loughran, TP; Malysz, J; Ochmann, M; Talamo, G	1
Hobeika, L; Self, SE; Velez, JC	1
Bacchiarri, F; Bosi, A; Donnini, I; Guarrera, A; Longo, G; Nozzoli, C; Staderini, M; Veltroni, A	1
Mukherjee, S; Ornstein, MC; Sekeres, MA	1
Camarero, J; Flores, B; Gisselbrecht, C; Hanaizi, Z; Hemmings, R; Laane, E; Pignatti, F; Salmonson, T; Sancho-Lopez, A	1
Arikian, SR; Binder, G; Corvino, FA; Gibson, CJ; Hu, XH; Hussein, M; Milentijevic, D; Nagarwala, Y; Surinach, A; Usmani, SZ	1
Bellotti, D; Boiocchi, L; Borlenghi, E; Cerqui, E; Imberti, L; Lamorgese, C; Pagani, C; Pelizzari, A; Rossi, G; Schieppati, F; Sottini, A	1
Bladé, J; Cibeira, MT; de la Rubia, J; Fernández de Larrea, C; Granell, M; Hernández, MT; Lahuerta, JJ; Mateos, MV; Oriol, A; San Miguel, JF	1
Ikebe, T; Itani, K; Miyazaki, Y; Nagamatsu, K; Ogata, M; Ohtsuka, E; Saburi, M; Saburi, Y	1
Amatya, R; Belch, A; Dimopoulos, M; Gibson, CJ; Jacques, C; Moreau, P; Palumbo, A; San Miguel, J; Schey, S; Song, KW; Sonneveld, P; Sternas, L; Weisel, K; Yu, X; Zaki, M	1
Arnulf, B; Bridoux, F; Caulier, A; Chevret, S; Cohen, C; El Karoui, K; Fermand, JP; Jaccard, A; Javaugue, V; Knebelmann, B; Royer, B; Szalat, R; Touchard, G	1
Kadowaki, M; Kohno, K; Okamura, S; Takase, K; Yamasaki, S	1
Garcia-Manero, G	1
Bartlett, NL; Blum, KA; Cheson, BD; Czuczman, M; Giguere, JK; Johnson, J; Jung, SH; Leonard, JP; Pitcher, BN	1
Aylı, M; Cengiz Seval, G; Özcan, M	1
Aschauer, G; Burgstaller, S; Fiegl, M; Fridrik, M; Girschikofsky, M; Greil, R; Keil, F; Linkesch, W; Nösslinger, T; Petzer, A; Stauder, R	1
Hazlehurst, L; Lynch, CC; Shay, G	1
Bagratuni, T; Dimopoulos, MA; Eleutherakis-Papaiakovou, E; Gavriatopoulou, M; Kalapanida, D; Kastritis, E; Liacos, CI; Matsouka, C; Migkou, M; Mparmparousi, D; Tasidou, A; Terpos, E	1
Boccadoro, M; Campbell, P; Carella, A; Catalano, L; Conticello, C; Corradini, P; Evangelista, A; Gay, F; Hajek, R; Liberati, AM; Magarotto, V; Malfitano, A; Offidani, M; Oliva, S; Omedè, P; Palumbo, A; Patriarca, F; Pescosta, N; Petrò, D; Petrucci, MT; Pour, L; Pulini, S; Ria, R; Siniscalchi, A; Spada, S; Spencer, A	1
Becht, R; Bołkun, Ł; Butrym, A; Błońska, D; Charliński, G; Dębski, J; Dmoszyńska, A; Druzd-Sitek, A; Dytfeld, D; Hałka, J; Hołojda, J; Hus, M; Januszczyk, J; Jurczyszyn, A; Knopińska-Posłuszny, W; Kuliczkowski, K; Kłoczko, J; Lech-Marańda, E; Legieć, W; Malenda, A; Nowicki, A; Pogrzeba, J; Rymko, M; Rzepecki, P; Stella-Hołowiecka, B; Subocz, E; Torosian, T; Urbanowicz, A; Urbańska-Ryś, H; Usnarska-Zubkiewicz, L; Zaucha, JM; Zdziarska, B; Zubkiewicz-Kucharska, A	1
Duvic, M	1
Belhadj, K; Bensinger, W; Chen, G; Cheung, MC; Derigs, HG; Dib, M; Dimopoulos, MA; Eom, H; Ervin-Haynes, A; Facon, T; Gamberi, B; Hall, R; Jaccard, A; Jardel, H; Karlin, L; Kolb, B; Lenain, P; Leupin, N; Liu, T; Marek, J; Rigaudeau, S; Roussel, M; Schots, R; Tosikyan, A; Van der Jagt, R	1
Alignani, D; Barcena, P; Barlogie, B; Blade, J; Burgos, L; Corchete, LA; De Arriba, F; Echeveste, MA; Epstein, J; García-Sanz, R; Gironella, M; Gonzalez, Y; Hernandez, MT; Johnson, SK; Lahuerta, JJ; Maiso, P; Mateos, MV; Ocio, EM; Orfao, A; Oriol, A; Paiva, B; Palomera, L; Puig, N; Rodriguez, I; San Miguel, JF; Sanchez, ML; Vidriales, MB	1
Berkova, Z; Champlin, RE; Cleeland, C; Feng, L; Mendoza, TR; Orlowski, RZ; Qazilbash, MH; Shah, JJ; Thomas, SK; Wang, M; Weber, DM	1
Al Ali, NH; Bart-Smith, E; Craig, BM; Epling-Burnette, PK; Komrokji, RS; Kordasti, S; Kulasekararaj, A; Lancet, JE; List, AF; Mufti, GJ; Padron, E; Pinilla-Ibarz, J; Zhang, L	1
Blank, J; Chang, JE; Eickhoff, J; Go, RS; Havighurst, T; Kahl, BS; Kim, K; Kirby-Slimp, R; Traynor, AM; Volk, LM; Weiss, M; Werndli, J	1
Chou, T; Ervin-Haynes, A; Hirata, H; Houck, V; Iida, S; Ikeda, T; Ishizawa, K; Matsue, K; Matsumoto, M; Matsumura, I; Midorikawa, S; Ogaki, Y; Ogawa, Y; Otsuka, M; Shimizu, T; Shinagawa, A; Suzuki, K; Takezako, N; Taniwaki, M; Terui, Y; Uchida, T	1
Beguin, Y; Caers, J; Decaux, O; Dimopoulos, M; Engelhardt, M; Fernández de Larrea, C; Heusschen, R; Jurczyszyn, A; Kastritis, E; Leleu, X; Ludwig, H; Mateos, MV; Minnema, M; Palumbo, A; Wäsch, R; Zojer, N	1
Jurczyszyn, A; Olszewska-Szopa, M; Skotnicki, AB	1
Al Ali, NH; Dalton, W; Fisher, K; Fulp, W; Hampras, SS; Kenvin, L; Knight, R; Komrokji, RS; Lancet, J; Lee, JH; List, A; Olesnyckyj, M; Padron, E; Rollison, DE; Shain, KH; Xu, Q	1
Cai, QQ; Guan, YZ; Li, J; Su, W; Wang, C; Zhou, DB	1
Chen, M; Dong, B; Dong, T; Guan, P; Li, J; Liu, T; Ma, H; Niu, T; Pan, L; Shuai, X; Valencia, CA; Wang, F; Wu, Y; Xiang, B; Xie, L; Zhang, L; Zhu, H; Zou, X	1
Azais, I; Belch, A; Chen, G; Dakhil, S; Dimopoulos, MA; Doyen, C; Dührsen, U; Eek, R; Ervin-Haynes, A; Facon, T; Garderet, L; Gisslinger, H; Goncalves, C; Houck, V; Hulin, C; Hunter, H; LeBlanc, R; Leleu, X; Leupin, N; Lu, J; Macro, M; Offner, F; Pégourié, B; Petrucci, MT; Rodon, P; Romeril, K; Royer, B; Shustik, C; Song, K	1
Cho, BS; Cho, SG; Eom, KS; Kim, DW; Kim, HJ; Kim, M; Kim, TW; Kim, YJ; Lee, JW; Lee, S; Lee, SE; Lim, JY; Min, CK; Min, WS; Ryu, DB; Yoon, JH	1
Badiali, S; Bari, A; Cocito, F; Corso, A; Gentile, M; Guarini, A; Marcheselli, L; Marcheselli, R; Mazzone, C; Mele, G; Minoia, C; Morabito, F; Musto, P; Palumbo, A; Pozzi, S; Ria, R; Rivolti, E; Sacchi, S; Vincelli, I	1
Abe, Y; Fujiwara, H; Imaizumi, Y; Ishida, T; Ishizawa, K; Ito, S; Jo, T; Midorikawa, S; Moriuchi, Y; Nosaka, K; Ogura, M; Ohtsu, T; Otsuka, M; Ruiz, W; Taira, N; Tobinai, K; Tsukasaki, K; Yoshimitsu, M	1
Bernardini, A; Boccadoro, M; Caravita, T; Conticello, C; Drandi, D; Ferrero, S; Gambella, M; Gay, F; Genuardi, M; Gilestro, M; Liberati, AM; Muccio, VE; Musto, P; Oliva, S; Omedè, P; Palumbo, A; Passera, R; Patriarca, F; Pautasso, C; Pescosta, N; Petrucci, MT; Rocci, A; Saraci, E	1
Boultwood, J; Dimitriou, M; Douagi, I; Giai, V; Grandien, A; Hellström-Lindberg, E; Jacobsen, SE; Jädersten, M; Jansson, M; Karimi, M; LeBlanc, K; Neuberg, DS; Pellagatti, A; Saft, L; Scharenberg, C; Woll, PS	1
Cavo, M; Mancuso, K; Pantani, L; Pezzi, A; Rizzello, I; Rocchi, S; Tacchetti, P; Zamagni, E; Zannetti, BA	1
Chen, G; Chen, WM; Eom, HS; Ervin-Haynes, A; Facon, T; Huang, SY; Hulin, C; Kim, HJ; Kim, K; Kwak, JY; Lee, JH; Lee, JJ; Lee, JO; Liu, T; Lu, J; Min, CK; Qiu, L; Shen, ZX; Yiu, W; Yoon, SS	1
Boudreault, JS; Moreau, P; Touzeau, C	1
Al Ali, N; Cluzeau, T; Fenaux, P; Gore, SD; Komrokji, R; Park, S; Prebet, T; Sekeres, MA; Sugrue, MM; Toma, A; Vey, N	1
Stahl, M; Zeidan, AM	1
Baker, B; Blacklock, H; Browett, P; Cannell, P; Corbett, G; Cowan, L; Dimopoulos, MA; Fernyhough, L; Forsyth, C; Harrison, S; Henderson, R; Link, E; Miles Prince, H; Neylon, A; Quach, H; Swern, A; Trotman, J; Underhill, C	1
Berchem, G; Giuliani, M; Janji, B	1
Amato, RJ; Hernandez-McClain, J; Khan, M; Saxena, S	1
Aarts, T; Emmelot, M; Lokhorst, HM; Minnema, MC; Mutis, T; van der Veer, MS	1
Booth, B; Dagher, R; Farrell, A; Hazarika, M; Justice, R; Pazdur, R; Rock, E; Sridhara, R; Williams, G	1
Hellström-Lindberg, E; Jädersten, M	1
Bargou, RC; Einsele, H; Falk, K; Gerecke, C; Glasmacher, A; Knop, S; Liebisch, P; Maeder, U; Platzbecker, U; Sezer, O; Topp, MS; Vollmuth, C	1
Croce, CM; Gorgun, G; Gribben, JG; Holderried, TA; Le Dieu, R; Liu, F; Quackenbush, J; Ramsay, AG; Zahrieh, D	1
Stone, RM	1
Anderson, KC; Badros, AZ; Bensinger, W; Berenson, J; Hussein, M; Irwin, D; Jagannath, S; Kenvin, L; Knight, R; Olesnyckyj, M; Richardson, P; Singhal, S; Vescio, R; Williams, SF; Yu, Z; Zeldis, J	1
List, A	1
Boultwood, J; Göhring, G; Hellström-Lindberg, E; Jädersten, M; Pellagatti, A; Porwit, A; Saft, L; Schlegelberger, B; Wainscoat, JS	1
Aul, C; Büsche, G; Giagounidis, A; Göhring, G; Hellström-Lindberg, E; Kreipe, HH; Schlegelberger, B; Zimmermann, M	1
Eisen, T; Glaspy, J; Hamilton, A; Hersey, P; Jungnelius, JU; Knight, RD; Millward, M; Trefzer, U	1
Eeltink, CM; Huls, G; Kersten, MJ; Kneppers, E; Koedam, J; Lokhorst, HM; Minnema, MC; Raymakers, RA; Schaafsma, MR; Sonneveld, P; van Oers, MH; Vellenga, E; Wijermans, PW; Wittebol, S; Zweegman, S	1
Boccadoro, M; Canepa, L; Crugnola, M; Falco, P; Falcone, AP; Federico, V; Genuardi, M; Larocca, A; Magarotto, V; Palumbo, A; Petrucci, MT; Sanpaolo, G	1
Komrokji, RS; Lancet, JE; List, AF	1
Hagemeister, FB	1
Goldschmidt, H; Heiss, C; Hielscher, T; Ho, AD; Klein, U; Neben, K	1
Theodorescu, D; Wilson, SS	1
Antonarakis, ES; Carducci, M; Denmeade, S; Drake, C; Eisenberger, M; Hudock, S; Keizman, D; Pili, R; Sinibaldi, V; Zahurak, M	1
Dimopoulos, MA; Terpos, E	1
Bravo, ML; Dimopoulos, MA; Harousseau, JL; Knight, RD; Olesnyckyj, M; Rajkumar, SV; San-Miguel, JF; Siegel, D; Stadtmauer, EA; Weber, DM; Zeldis, JB	1
Bauer, F; Dasanu, CA; Davis, LK; Reale, MA; Schwartz, RA; Silver, JS	1
Balin, SJ; Kurtin, PJ; Letendre, L; Pittelkow, MR; Wetter, DA	1
Allred, J; Bergsagel, PL; Buadi, FK; Dingli, D; Dispenzieri, A; Fonseca, R; Gertz, MA; Greipp, PR; Hayman, SR; Kumar, SK; Lacy, MQ; Laumann, K; Lust, JA; Mikhael, JR; Rajkumar, SV; Reeder, CB; Russell, SJ; Stewart, K; Witzig, TE; Zeldenrust, SR	1
Dimopoulos, MA; Hussein, M; Swern, AS; Weber, D	1
Antonarakis, ES; Carducci, M; Drake, CG; Eisenberger, MA; Keizman, D; McNeel, DG; Smith, HA; Thoburn, CJ; Zabransky, DJ; Zahurak, M	1
Büsche, G; Giagounidis, A; Göhring, G; Hellström-Lindberg, E; Hofmann, W; Kreipe, H; Lange, K; Morgan, M; Nielsen, KV; Roy, L; Schlegelberger, B	1
Adès, L; Banos, A; Blanc, M; Bouscary, D; Bresler, AG; Cabrol, MP; Chevret, S; Delaunay, J; Delmer, A; Dreyfus, F; Eclache, V; Fenaux, P; Kelaidi, C; Lamy, T; Le Bras, F; Sebert, M; Turlure, P; Vey, N; Visanica, S; Wattel, E	1
Fenaux, P; Freeman, J; Palumbo, A; Weiss, L	1
Blin, N; Clavert, A; Dubruille, V; Le Gouill, S; Loirat, M; Mahe, B; Malard, F; Mohty, M; Moreau, P; Pennetier, M; Peterlin, P; Planche, L; Roland, V; Tessoulin, B; Touzeau, C	1
Aguado, B; Alegre, A; Cibeira, MT; Garcia-Larana, J; Knight, R; Martinez-Chamorro, C; Mateos, MV; Oriol-Rocafiguera, A; Rosettani, B; Sureda, A	1
Facon, T; Harousseau, JL; Jagannath, S; Kaufman, JL; Leleu, X; Lonial, S; Mazumder, A; Moreau, P; Singhal, AK; Tsao, LC; Vij, R; Westland, C	1
Matsuoka, A; Tohyama, K; Tohyama, Y; Tsujioka, T	1
Borrello, I; Chanan-Khan, AA; Dimopoulos, M; Foà, R; Hellmann, A; Knight, R; Lonial, S; Swern, AS; Weber, D	1
Chen, C; Jimenez-Zepeda, VH; Kukreti, V; Reece, DE; Tiedemann, R; Trudel, S	1
Brower, V	1
Atanackovic, D; Ayuk, F; Dreger, P; Hegenbart, U; Heinzelmann, M; Hildebrandt, Y; Kröger, N; Schönland, S; Stübig, T; Wolschke, C; Zander, A	1
Patel, JM; Sanchorawala, V; Seldin, DC; Shelton, AC; Sloan, JM; Zeldis, JB	1
Ludwig, H; Sonneveld, P	1
Backstrom, J; Brandenburg, NA; Fenaux, P; Germing, U; Giagounidis, AA; Glasmacher, A; Hasford, J; Kuendgen, A; Lauseker, M; List, AF	1
Alsina, M; Anderson, KC; Bensinger, W; Biermann, JS; Cohen, AD; Devine, S; Djulbegovic, B; Faber, EA; Gasparetto, C; Hernandez-Illizaliturri, F; Huff, CA; Kassim, A; Krishnan, AY; Kumar, R; Liedtke, M; Meredith, R; Raje, N; Schriber, J; Shead, DA; Singhal, S; Somlo, G; Stockerl-Goldstein, K; Treon, SP; Weber, D; Yahalom, J; Yunus, F	1
Anderson, KC	2
Kyle, RA; Rajkumar, SV	1
Allred, JB; Dispenzieri, A; Gertz, MA; Geyer, SM; Greipp, PR; Hayman, SR; Kabat, B; Kumar, SK; Lacy, MQ; Lust, JA; Rajkumar, SV; Russell, SJ; Witzig, TE; Zeldenrust, SR	1
Alatakis, S; Bishton, MJ; Januszewicz, H; Liew, MS; Prince, HM	1
Bergsagel, PL; Dispenzieri, A; Fonseca, R; Gertz, MA; Geyer, S; Greipp, PR; Hayman, SR; Kabat, B; Kumar, S; Kyle, RA; Lacy, MQ; Lust, JA; Rajkumar, SV; Russell, SJ; Stewart, AK; Witzig, TE; Zeldenrust, SR	1
Chen, N; Knight, R; Kong, L; Kumar, G; Laskin, OL; Lau, H; Zeldis, JB	1
Attal, M; Corso, A; Dimopoulos, M; Dmoszynska, A; Facon, T; Foà, R; Harousseau, JL; Hellmann, A; Knight, RD; Masliak, Z; Olesnyckyj, M; Patin, J; Prince, HM; San Miguel, J; Spencer, A; Yu, Z; Zeldis, JB	1
Belch, A; Borrello, I; Chanan-Khan, AA; Chen, C; Knight, RD; Lonial, S; Niesvizky, R; Olesnyckyj, M; Patin, J; Rajkumar, SV; Siegel, D; Stadtmauer, EA; Wang, M; Weber, DM; Yu, Z; Zeldis, JB	1
Faiman, B	1
Bladé, J; Hajek, R; Harousseau, JL; Nagler, A; Orlowski, RZ; Robak, T; Sonneveld, P; Spencer, A; Zhuang, SH	1
Batts, ED; Hegerfeldt, Y; Lazarus, HM; Sanchorawala, V	1

Reviews

35 review(s) available for lenalidomide and Disease Exacerbation

Article	Year
The benefits of early intervention using lenalidomide for high-risk smoldering multiple myeloma: emerging data and its promising clinical impact. Expert review of hematology, 2021, Volume: 14, Issue:12 Topics: Disease Progression; Humans; Lenalidomide; Monoclonal Gammopathy of Undetermined Significance; Multiple Myeloma; Quality of Life; Smoldering Multiple Myeloma	2021
Early Progressing Follicular Lymphoma. Current oncology reports, 2021, 11-19, Volume: 23, Issue:12 Topics: Antineoplastic Combined Chemotherapy Protocols; Disease Progression; Humans; Lenalidomide; Lymphoma, Follicular; Phosphoinositide-3 Kinase Inhibitors	2021
The effect of intervention versus watchful waiting on disease progression and overall survival in smoldering multiple myeloma: a systematic review of randomized controlled trials. Journal of cancer research and clinical oncology, 2022, Volume: 148, Issue:4 Topics: Disease Progression; Humans; Lenalidomide; Randomized Controlled Trials as Topic; Smoldering Multiple Myeloma; Watchful Waiting	2022
Smoldering multiple myeloma current treatment algorithms. Blood cancer journal, 2022, 09-05, Volume: 12, Issue:9 Topics: Algorithms; Biological Products; Disease Progression; Humans; Lenalidomide; Monoclonal Gammopathy of Undetermined Significance; Multiple Myeloma; Paraproteinemias; Smoldering Multiple Myeloma	2022
High-risk smoldering myeloma versus early detection of multiple myeloma: Current models, goals of therapy, and clinical implications. Best practice & research. Clinical haematology, 2020, Volume: 33, Issue:1 Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Dexamethasone; Disease Progression; Drug Administration Schedule; Early Detection of Cancer; Humans; Lenalidomide; Monoclonal Gammopathy of Undetermined Significance; Multiple Myeloma; Neoplasm, Residual; Oligopeptides; Plasma Cells; Randomized Controlled Trials as Topic; Smoldering Multiple Myeloma; Survival Analysis	2020
Genetics of progression from MDS to secondary leukemia. Blood, 2020, 07-02, Volume: 136, Issue:1 Topics: Cell Count; Clonal Evolution; Disease Progression; DNA Methylation; DNA Mutational Analysis; Epigenesis, Genetic; Exome Sequencing; Hematopoietic Stem Cells; Humans; Lenalidomide; Leukemia, Myeloid, Acute; Mutation; Myelodysplastic Syndromes; Myelopoiesis; Neoplastic Stem Cells; Prognosis; Tumor Burden; Whole Genome Sequencing	2020
Psychological distress among health care professionals of the three COVID-19 most affected Regions in Cameroon: Prevalence and associated factors. Annales medico-psychologiques, 2021, Volume: 179, Issue:2 Topics: 3' Untranslated Regions; 5'-Nucleotidase; A549 Cells; Accidental Falls; Acetylcholinesterase; Acrylic Resins; Actinobacillus; Acute Disease; Acute Kidney Injury; Adaptor Proteins, Signal Transducing; Adenosine; Adenosine Triphosphate; Administration, Inhalation; Administration, Oral; Adolescent; Adult; Advance Care Planning; Africa, Northern; Age Factors; Aged; Aged, 80 and over; Air Pollutants; Air Pollution; Air Pollution, Indoor; Albendazole; Aluminum Oxide; Anastomosis, Surgical; Ancylostoma; Ancylostomiasis; Androstadienes; Angiogenesis Inhibitors; Angiotensin II; Animals; Anti-Bacterial Agents; Anti-Infective Agents; Antibodies, Bispecific; Antibodies, Viral; Anticoagulants; Antihypertensive Agents; Antinematodal Agents; Antineoplastic Agents; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Antioxidants; Antiporters; Antiviral Agents; Apoptosis; Aptamers, Nucleotide; Aromatase Inhibitors; Asian People; Astrocytes; Atrial Fibrillation; Auditory Threshold; Aurora Kinase B; Australia; Autophagy; Autophagy-Related Protein 5; Autotrophic Processes; Bacillus cereus; Bacillus thuringiensis; Bacterial Proteins; Beclin-1; Belgium; Benzene; Benzene Derivatives; Benzhydryl Compounds; beta Catenin; beta-Arrestin 2; Biliary Tract Diseases; Biofilms; Biofuels; Biomarkers; Biomarkers, Tumor; Biomass; Biomechanical Phenomena; Bioreactors; Biosensing Techniques; Biosynthetic Pathways; Bismuth; Blood Platelets; Bone and Bones; Bone Regeneration; Bortezomib; Botulinum Toxins, Type A; Brain; Brain Injuries; Brain Ischemia; Brain Neoplasms; Breast Neoplasms; Breath Tests; Bronchodilator Agents; Calcium Phosphates; Cannabis; Carbon Dioxide; Carbon Isotopes; Carcinogenesis; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cardiac Resynchronization Therapy; Cardiac Resynchronization Therapy Devices; Cardiomyopathies; Cardiovascular Diseases; Cariostatic Agents; Case Managers; Case-Control Studies; Catalysis; Cation Transport Proteins; CD8-Positive T-Lymphocytes; Cecropia Plant; Cell Adhesion; Cell Count; Cell Differentiation; Cell Division; Cell Line; Cell Line, Tumor; Cell Membrane; Cell Movement; Cell Proliferation; Cell Self Renewal; Cell Survival; Cells, Cultured; Cellular Reprogramming; Cellulose; Charcoal; Chemical and Drug Induced Liver Injury; Chemical Phenomena; Chemokines; Chemoradiotherapy; Chemoreceptor Cells; Child; Child Abuse; Child, Preschool; China; Chlorogenic Acid; Chloroquine; Chromatography, Gas; Chronic Disease; Clinical Competence; Coated Materials, Biocompatible; Cochlea; Cohort Studies; Color; Comorbidity; Computer Simulation; Computer-Aided Design; Contraception; Contraceptive Agents, Female; Contrast Media; COP-Coated Vesicles; Coronavirus Infections; Cost of Illness; Coturnix; COVID-19; Creatinine; Cross-Over Studies; Cross-Sectional Studies; Culex; Curriculum; Cyclic N-Oxides; Cytokines; Cytoplasm; Cytotoxicity, Immunologic; Cytotoxins; Databases, Factual; Deep Learning; Delivery, Obstetric; Denitrification; Dental Caries; Denture, Complete; Dexamethasone; Diabetes Complications; Diabetes Mellitus; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Dielectric Spectroscopy; Diet, High-Fat; Dietary Fiber; Disease Models, Animal; Disease Progression; DNA; DNA Copy Number Variations; DNA, Mitochondrial; Dog Diseases; Dogs; Dopaminergic Neurons; Double-Blind Method; Down-Regulation; Doxorubicin; Drug Carriers; Drug Design; Drug Interactions; Drug Resistance, Bacterial; Drug Resistance, Neoplasm; Drug-Related Side Effects and Adverse Reactions; Drugs, Chinese Herbal; Dry Powder Inhalers; Dust; E2F1 Transcription Factor; Ecosystem; Education, Nursing; Education, Nursing, Baccalaureate; Electric Impedance; Electricity; Electrocardiography; Electrochemical Techniques; Electrochemistry; Electrodes; Electrophoresis, Polyacrylamide Gel; Endoplasmic Reticulum; Endothelial Cells; Environmental Monitoring; Enzyme Inhibitors; Epithelial Cells; Epithelial-Mesenchymal Transition; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Estrogen Receptor Modulators; Europe; Evoked Potentials, Auditory, Brain Stem; Exosomes; Feasibility Studies; Female; Ferricyanides; Ferrocyanides; Fibrinogen; Finite Element Analysis; Fistula; Fluorescent Dyes; Fluorides, Topical; Fluorodeoxyglucose F18; Fluticasone; Follow-Up Studies; Food Contamination; Food Microbiology; Foods, Specialized; Forensic Medicine; Frail Elderly; France; Free Radicals; Fresh Water; Fungi; Fungicides, Industrial; Galactosamine; Gastrointestinal Neoplasms; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Gene Frequency; Genetic Predisposition to Disease; Genotype; Gingival Hemorrhage; Glioblastoma; Glioma; Glomerular Filtration Rate; Glomerulosclerosis, Focal Segmental; Glucose; Glucose Transport Proteins, Facilitative; Glucosides; Glutamine; Glycolysis; Gold; GPI-Linked Proteins; Gram-Negative Bacteria; Gram-Positive Bacteria; Graphite; Haplotypes; HCT116 Cells; Healthy Volunteers; Hearing Loss; Heart Failure; Hedgehog Proteins; HEK293 Cells; HeLa Cells; Hemodynamics; Hemorrhage; Hepatocytes; Hippo Signaling Pathway; Histone Deacetylases; Homeostasis; Hospital Mortality; Hospitalization; Humans; Hydantoins; Hydrazines; Hydrogen Peroxide; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Hydroxylamines; Hypoglycemic Agents; Immunity, Innate; Immunoglobulin G; Immunohistochemistry; Immunologic Factors; Immunomodulation; Immunophenotyping; Immunotherapy; Incidence; Indazoles; Indonesia; Infant; Infant, Newborn; Infarction, Middle Cerebral Artery; Inflammation; Injections, Intramuscular; Insecticides; Insulin-Like Growth Factor I; Insurance, Health; Intention to Treat Analysis; Interleukin-1 Receptor-Associated Kinases; Interleukin-6; Intrauterine Devices; Intrauterine Devices, Copper; Iron; Ischemia; Jordan; Keratinocytes; Kidney; Kidney Diseases; Kir5.1 Channel; Klebsiella Infections; Klebsiella pneumoniae; Lab-On-A-Chip Devices; Laparoscopy; Lasers; Lasers, Semiconductor; Lenalidomide; Leptin; Lethal Dose 50; Levonorgestrel; Limit of Detection; Lipid Metabolism; Lipid Metabolism Disorders; Lipogenesis; Lipopolysaccharides; Liquid Biopsy; Liver; Liver Abscess, Pyogenic; Liver Cirrhosis; Liver Diseases; Liver Neoplasms; Longevity; Lung Neoplasms; Luteolin; Lymph Nodes; Lymphocyte Activation; Macaca fascicularis; Macrophages; Mad2 Proteins; Magnetic Resonance Imaging; Male; Mammary Glands, Human; Manganese; Manganese Compounds; MAP Kinase Signaling System; Materials Testing; Maternal Health Services; MCF-7 Cells; Medicaid; Medicine, Chinese Traditional; Melanoma; Membrane Proteins; Mental Health; Mercury; Metal Nanoparticles; Metals, Heavy; Metformin; Methionine Adenosyltransferase; Mice; Mice, Inbred BALB C; Mice, Inbred C3H; Mice, Inbred C57BL; Mice, Inbred CBA; Mice, Knockout; Mice, Nude; Microalgae; Microbial Sensitivity Tests; Microglia; MicroRNAs; Microscopy, Atomic Force; Microscopy, Electron, Scanning; Middle Aged; Mitochondria; Mitochondrial Proteins; Mitral Valve; Mitral Valve Insufficiency; Models, Anatomic; Molecular Structure; Molybdenum; Monocarboxylic Acid Transporters; Moths; MPTP Poisoning; Multigene Family; Multiparametric Magnetic Resonance Imaging; Multiple Myeloma; Muscle, Skeletal; Mutagens; Mutation; Myeloid Cells; Nanocomposites; Nanofibers; Nanomedicine; Nanoparticles; Nanowires; Neoadjuvant Therapy; Neomycin; Neoplasm Grading; Neoplasm Recurrence, Local; Neoplasms; Neoplastic Stem Cells; Neostriatum; Neovascularization, Pathologic; Netherlands; Neuromuscular Agents; Neurons; NF-E2-Related Factor 2; NF-kappa B; Nickel; Nitrogen Oxides; Non-alcoholic Fatty Liver Disease; Nucleosides; Nucleotidyltransferases; Nutritional Status; Obesity, Morbid; Ofloxacin; Oils, Volatile; Oligopeptides; Oncogene Protein v-akt; Optical Imaging; Organic Cation Transport Proteins; Organophosphonates; Osteoarthritis; Osteoarthritis, Hip; Osteoarthritis, Knee; Osteoblasts; Osteogenesis; Oxidation-Reduction; Oxidative Stress; Oxides; Oxygen Isotopes; Pancreas; Pancreaticoduodenectomy; Pandemics; Particle Size; Particulate Matter; Patient Acceptance of Health Care; Patient Compliance; PC-3 Cells; Peptide Fragments; Peptides; Periodontal Attachment Loss; Periodontal Index; Periodontal Pocket; Periodontitis; Peroxides; Peru; Pest Control, Biological; Phosphatidylinositol 3-Kinase; Phosphatidylinositol 3-Kinases; Phylogeny; Pilot Projects; Piperidines; Plant Bark; Plant Extracts; Plant Leaves; Plasmids; Platelet Function Tests; Pneumonia, Viral; Podocytes; Poly (ADP-Ribose) Polymerase-1; Poly(ADP-ribose) Polymerase Inhibitors; Polyethylene Terephthalates; Polymers; Polymorphism, Single Nucleotide; Porosity; Portugal; Positron-Emission Tomography; Postoperative Complications; Postural Balance; Potassium Channels, Inwardly Rectifying; Povidone; Powders; Precancerous Conditions; Precision Medicine; Predictive Value of Tests; Pregnancy; Prenatal Care; Prognosis; Promoter Regions, Genetic; Prospective Studies; Prostatectomy; Prostatic Neoplasms; Proteasome Inhibitors; Protective Agents; Protein Binding; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Protein Transport; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins c-akt; Psychiatric Nursing; PTEN Phosphohydrolase; Pulmonary Embolism; Pyrimethamine; Radiopharmaceuticals; Rats; Rats, Sprague-Dawley; Rats, Wistar; Reactive Oxygen Species; Receptor, ErbB-2; Receptor, IGF Type 1; Receptors, Estrogen; Receptors, G-Protein-Coupled; Recombinational DNA Repair; Recovery of Function; Regional Blood Flow; Renal Dialysis; Renin; Renin-Angiotensin System; Reperfusion Injury; Reproducibility of Results; Republic of Korea; Respiratory Distress Syndrome; Retrospective Studies; Rhodamines; Risk Assessment; Risk Factors; RNA, Long Noncoding; RNA, Messenger; Running; Saccharomyces cerevisiae; Saccharomyces cerevisiae Proteins; Salinity; Salmeterol Xinafoate; Sarcoma; Seasons; Shoulder Injuries; Signal Transduction; Silicon Dioxide; Silver; Sirtuin 1; Sirtuins; Skull Fractures; Social Determinants of Health; Sodium; Sodium Fluoride; Sodium Potassium Chloride Symporter Inhibitors; Sodium-Glucose Transporter 2 Inhibitors; Soil; Soil Pollutants; Spain; Spectrophotometry; Spectroscopy, Fourier Transform Infrared; Staphylococcal Protein A; Staphylococcus aureus; Stem Cells; Stereoisomerism; Stomach Neoplasms; Streptomyces; Strontium; Structure-Activity Relationship; Students, Nursing; Substance-Related Disorders; Succinic Acid; Sulfur; Surface Properties; Survival Rate; Survivin; Symporters; T-Lymphocytes; Temozolomide; Tensile Strength; Thiazoles; Thiobacillus; Thiohydantoins; Thiourea; Thrombectomy; Time Factors; Titanium; Tobacco Mosaic Virus; Tobacco Use Disorder; Toll-Like Receptor 4; Toluene; Tomography, X-Ray Computed; TOR Serine-Threonine Kinases; Toxicity Tests, Acute; Toxicity Tests, Subacute; Transcriptional Activation; Treatment Outcome; Troponin I; Tumor Cells, Cultured; Tumor Escape; Tumor Hypoxia; Tumor Microenvironment; Tumor Necrosis Factor Inhibitors; Tumor Necrosis Factor-alpha; Tyrosine; Ubiquitin-Protein Ligases; Ubiquitination; Ultrasonic Waves; United Kingdom; United States; United States Department of Veterans Affairs; Up-Regulation; Urea; Uric Acid; Urinary Bladder Neoplasms; Urinary Bladder, Neurogenic; Urine; Urodynamics; User-Computer Interface; Vemurafenib; Verbenaceae; Veterans; Veterans Health; Viral Load; Virtual Reality; Vitiligo; Water Pollutants, Chemical; Wildfires; Wnt Signaling Pathway; Wound Healing; X-Ray Diffraction; Xenograft Model Antitumor Assays; Xylenes; Young Adult; Zinc; Zinc Oxide; Zinc Sulfate; Zoonoses	2021
Mechanisms of lenalidomide sensitivity and resistance. Experimental hematology, 2020, Volume: 91 Topics: Adaptor Proteins, Signal Transducing; Anemia, Macrocytic; Angiogenesis Inhibitors; Antineoplastic Agents; Autophagy; Cell Differentiation; Chromosome Deletion; Chromosomes, Human, Pair 5; Cytokines; Disease Progression; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Humans; Ikaros Transcription Factor; Immunologic Factors; Lenalidomide; Megakaryocytes; Multiple Myeloma; Neoplasm Proteins; Neovascularization, Pathologic; Phosphoprotein Phosphatases; Ubiquitin-Protein Ligases	2020
Lenalidomide Maintenance After Autologous Stem-Cell Transplantation in Newly Diagnosed Multiple Myeloma: A Meta-Analysis. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2017, Oct-10, Volume: 35, Issue:29 Topics: Adult; Aged; Angiogenesis Inhibitors; Chemotherapy, Adjuvant; Disease Progression; Disease-Free Survival; Drug Administration Schedule; Female; Humans; Kaplan-Meier Estimate; Lenalidomide; Maintenance Chemotherapy; Male; Middle Aged; Multiple Myeloma; Randomized Controlled Trials as Topic; Risk Factors; Stem Cell Transplantation; Thalidomide; Time Factors; Transplantation, Autologous; Treatment Outcome; Young Adult	2017
A decade of progress in myelodysplastic syndrome with chromosome 5q deletion. Leukemia, 2018, Volume: 32, Issue:7 Topics: Animals; Chromosome Aberrations; Chromosome Deletion; Chromosomes, Human, Pair 5; Disease Management; Disease Progression; Drug Development; Genetic Heterogeneity; Genetic Predisposition to Disease; Humans; Lenalidomide; Leukemia, Myeloid, Acute; Mutation; Myelodysplastic Syndromes; Prognosis; Treatment Outcome; Tumor Suppressor Protein p53	2018
Current and Future Treatment Options for Myelodysplastic Syndromes: More Than Hypomethylating Agents and Lenalidomide? Drugs, 2018, Volume: 78, Issue:18 Topics: Disease Progression; DNA Methylation; Humans; Immunotherapy; Lenalidomide; Molecular Targeted Therapy; Myelodysplastic Syndromes; Transplantation, Homologous	2018
Treatment of MDS. Blood, 2019, 03-07, Volume: 133, Issue:10 Topics: Disease Progression; Erythropoiesis; Hematology; Hematopoietic Stem Cell Transplantation; Humans; Intercellular Signaling Peptides and Proteins; Iron Chelating Agents; Lenalidomide; Methylation; Myelodysplastic Syndromes; Prognosis; Risk; Severity of Illness Index; Translational Research, Biomedical; Transplantation, Homologous	2019
Lenalidomide as a disease-modifying agent in patients with del(5q) myelodysplastic syndromes: linking mechanism of action to clinical outcomes. Annals of hematology, 2014, Volume: 93, Issue:1 Topics: Angiogenesis Inhibitors; Apoptosis; Bone Marrow; Chromosome Deletion; Chromosomes, Human, Pair 5; Clinical Trials as Topic; Clone Cells; Disease Progression; Erythropoiesis; Gene Dosage; Genes, Tumor Suppressor; Humans; Immunologic Factors; Lenalidomide; Leukemia, Myeloid, Acute; Molecular Targeted Therapy; Myelodysplastic Syndromes; Survival Analysis; Thalidomide; Treatment Outcome; Tumor Suppressor Protein p53; Tumor Suppressor Proteins	2014
[Myelodysplastic syndromes: treatment strategy up-to-date]. [Rinsho ketsueki] The Japanese journal of clinical hematology, 2014, Volume: 55, Issue:1 Topics: Antilymphocyte Serum; Azacitidine; Benzoates; Cyclosporine; Cytarabine; Deferasirox; Disease Progression; Drug Discovery; Drug Therapy, Combination; Erythropoietin; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Humans; Idarubicin; Immunosuppressive Agents; Iron Chelating Agents; Lenalidomide; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Quality of Life; Risk Assessment; Thalidomide; Triazoles	2014
Current and future therapeutic approach for Waldenström's macroglobulinemia. Immunotherapy, 2014, Volume: 6, Issue:3 Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antimetabolites, Antineoplastic; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Comorbidity; Disease Progression; Everolimus; Forecasting; Guillain-Barre Syndrome; Hematopoietic Stem Cell Transplantation; Histone Deacetylase Inhibitors; Humans; Immunologic Factors; Immunotherapy; Incidence; Lenalidomide; Myelin-Associated Glycoprotein; Protein Kinase Inhibitors; Pyrazines; Rituximab; Salvage Therapy; Sirolimus; Thalidomide; Transplantation, Autologous; Treatment Outcome; Waldenstrom Macroglobulinemia; Watchful Waiting	2014
More is better: combination therapies for myelodysplastic syndromes. Best practice & research. Clinical haematology, 2015, Volume: 28, Issue:1 Topics: Antineoplastic Agents; Azacitidine; Benzamides; Clinical Trials as Topic; Decitabine; Disease Progression; Drug Therapy, Combination; Gene Expression; Histone Deacetylase Inhibitors; Histone Deacetylases; Humans; Hydroxamic Acids; Lenalidomide; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Pyrimidines; Thalidomide; Valproic Acid; Vorinostat	2015
The European medicines agency review of pomalidomide in combination with low-dose dexamethasone for the treatment of adult patients with multiple myeloma: summary of the scientific assessment of the committee for medicinal products for human use. The oncologist, 2015, Volume: 20, Issue:3 Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Disease Progression; Drug Resistance, Neoplasm; Europe; Humans; Lenalidomide; Multiple Myeloma; Neoplasm Recurrence, Local; Pyrazines; Survival Rate; Thalidomide	2015
Myelodysplastic syndromes: 2015 Update on diagnosis, risk-stratification and management. American journal of hematology, 2015, Volume: 90, Issue:9 Topics: Antimetabolites, Antineoplastic; Azacitidine; Bone Marrow; Decitabine; Disease Management; Disease Progression; Hematopoietic Stem Cell Transplantation; Humans; Intercellular Signaling Peptides and Proteins; Karyotype; Lenalidomide; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Research Design; Thalidomide; Transplantation, Homologous	2015
Dissecting the multiple myeloma-bone microenvironment reveals new therapeutic opportunities. Journal of molecular medicine (Berlin, Germany), 2016, Volume: 94, Issue:1 Topics: Bone and Bones; Bone Marrow; Bortezomib; Disease Progression; Drug Resistance, Neoplasm; Humans; Lenalidomide; Molecular Targeted Therapy; Multiple Myeloma; Oligopeptides; Proteasome Inhibitors; Thalidomide; Tumor Microenvironment	2016
The Changing Landscape of Smoldering Multiple Myeloma: A European Perspective. The oncologist, 2016, Volume: 21, Issue:3 Topics: Antineoplastic Agents; Biomarkers, Tumor; Dexamethasone; Diphosphonates; Disease Progression; Europe; Humans; Immunoglobulin Light Chains; Lenalidomide; Multiple Myeloma; Myeloma Proteins; Risk Factors; Thalidomide; Tumor Burden	2016
[Significant changes in diagnostic and therapeutic procedures in smoldering multiple myeloma]. Przeglad lekarski, 2015, Volume: 72, Issue:11 Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Dexamethasone; Disease Progression; Humans; Lenalidomide; Multiple Myeloma; Prognosis; Thalidomide	2015
Triplet combinations in relapsed/refractory myeloma: update on recent phase 3 trials. Expert review of hematology, 2017, Volume: 10, Issue:3 Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Clinical Trials, Phase III as Topic; Disease Progression; Drug Resistance, Neoplasm; Histone Deacetylase Inhibitors; Humans; Immunologic Factors; Lenalidomide; Multiple Myeloma; Neoplasm Staging; Proteasome Inhibitors; Recurrence; Retreatment; Thalidomide; Treatment Outcome	2017
Lenalidomide use in myelodysplastic syndromes: Insights into the biologic mechanisms and clinical applications. Cancer, 2017, 05-15, Volume: 123, Issue:10 Topics: Anemia; Antimetabolites, Antineoplastic; Azacitidine; Chromosomes, Human, Pair 5; Disease Progression; Humans; Immunologic Factors; Lenalidomide; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Thalidomide; Treatment Outcome	2017
Activation of NK cells and disruption of PD-L1/PD-1 axis: two different ways for lenalidomide to block myeloma progression. Oncotarget, 2017, Apr-04, Volume: 8, Issue:14 Topics: Animals; B7-H1 Antigen; Disease Progression; Humans; Killer Cells, Natural; Lenalidomide; Multiple Myeloma; Programmed Cell Death 1 Receptor; Thalidomide	2017
Myelodysplastic syndromes: biology and treatment. Journal of internal medicine, 2009, Volume: 265, Issue:3 Topics: Antineoplastic Agents; Blood Transfusion; Chromosomes, Human, Pair 5; Disease Progression; Erythropoietin; Female; Humans; Immunosuppressive Agents; Iron Chelating Agents; Lenalidomide; Male; Myelodysplastic Syndromes; Recombinant Proteins; Sequence Deletion; Thalidomide; World Health Organization	2009
How I treat patients with myelodysplastic syndromes. Blood, 2009, Jun-18, Volume: 113, Issue:25 Topics: Acute Disease; Aged; Azacitidine; Chelation Therapy; Chromosome Deletion; Chromosomes, Human, Pair 5; Clinical Trials as Topic; Decitabine; Disease Progression; DNA Methylation; Erythropoietin; Hematopoietic Cell Growth Factors; Hematopoietic Stem Cell Transplantation; Humans; Iron Chelating Agents; Lenalidomide; Leukemia, Myeloid; Myelodysplastic Syndromes; Severity of Illness Index; Thalidomide; Transplantation, Homologous	2009
Lenalidomide--a transforming therapeutic agent in myelodysplastic syndromes. Clinical lymphoma & myeloma, 2009, Volume: 9 Suppl 3 Topics: Antineoplastic Agents; Chromosome Deletion; Clinical Trials as Topic; Disease Progression; Humans; Immunosuppression Therapy; Karyotyping; Lenalidomide; Leukemia, Myeloid, Acute; Medical Oncology; Myelodysplastic Syndromes; Risk; Thalidomide; Treatment Outcome	2009
Lenalidomide in myelodysplastic syndromes: an erythropoiesis-stimulating agent or more? Current hematologic malignancy reports, 2010, Volume: 5, Issue:1 Topics: Anemia; Blood Transfusion; Chromosome Deletion; Chromosomes, Human, Pair 5; Clinical Trials as Topic; Clone Cells; Combined Modality Therapy; Disease Progression; Erythropoiesis; Humans; Immunologic Factors; Lenalidomide; Myelodysplastic Syndromes; Risk; Survival Analysis; Thalidomide	2010
Maintenance and consolidation strategies in non-Hodgkin's lymphoma: A review of the data. Current oncology reports, 2010, Volume: 12, Issue:6 Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cancer Vaccines; Combined Modality Therapy; Disease Progression; Disease-Free Survival; Everolimus; Hematopoietic Stem Cell Transplantation; Humans; Indoles; Lenalidomide; Lymphoma, Non-Hodgkin; Protein-Tyrosine Kinases; Radioimmunotherapy; Randomized Controlled Trials as Topic; Risk Factors; Rituximab; Secondary Prevention; Signal Transduction; Sirolimus; Survival Rate; Thalidomide; Treatment Outcome	2010
Rare bladder tumors: caveat emptor. Oncology (Williston Park, N.Y.), 2010, Volume: 24, Issue:9 Topics: Abnormalities, Drug-Induced; Disease Progression; Female; Humans; Lenalidomide; Male; Multiple Myeloma; Plasmacytoma; Pregnancy; Radiotherapy; Salvage Therapy; Thalidomide; Urinary Bladder; Urinary Bladder Neoplasms	2010
The clinical safety of lenalidomide in multiple myeloma and myelodysplastic syndromes. Expert opinion on drug safety, 2012, Volume: 11, Issue:1 Topics: Administration, Oral; Antineoplastic Agents; Disease Progression; Dose-Response Relationship, Drug; Humans; Lenalidomide; Multiple Myeloma; Myelodysplastic Syndromes; Product Surveillance, Postmarketing; Renal Insufficiency; Thalidomide; Time Factors	2012
Approach to new therapeutics: investigation by the use of MDS-derived cell lines. Current pharmaceutical design, 2012, Volume: 18, Issue:22 Topics: Animals; Cell Line; Chromosome Deletion; Chromosomes, Human, Pair 5; Disease Progression; DNA Modification Methylases; Enzyme Inhibitors; Gene Expression Profiling; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Thalidomide	2012
Disease control in patients with relapsed and/or refractory multiple myeloma: what is the optimal duration of therapy? Leukemia research, 2012, Volume: 36 Suppl 1 Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Calibration; Disease Progression; Drug Administration Schedule; Drug Resistance, Neoplasm; Humans; Lenalidomide; Maintenance Chemotherapy; Multiple Myeloma; Pyrazines; Recurrence; Thalidomide; Time Factors	2012
Multiple myeloma. The New England journal of medicine, 2004, Oct-28, Volume: 351, Issue:18 Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Combined Modality Therapy; Disease Progression; Humans; Lenalidomide; Multiple Myeloma; Paraproteinemias; Protease Inhibitors; Pyrazines; Remission Induction; Stem Cell Transplantation; Thalidomide	2004
Clinical updates and nursing considerations for patients with multiple myeloma. Clinical journal of oncology nursing, 2007, Volume: 11, Issue:6 Topics: Anti-Inflammatory Agents; Antineoplastic Agents; Boronic Acids; Bortezomib; Diagnosis, Differential; Disease Progression; Doxorubicin; Drug Administration Schedule; Humans; Lenalidomide; Melphalan; Multiple Myeloma; Neoplasm Staging; Nurse's Role; Oncology Nursing; Patient Compliance; Patient Education as Topic; Practice Guidelines as Topic; Prednisone; Pyrazines; Quality of Life; Survival Rate; Thalidomide; Treatment Outcome	2007

Trials

64 trial(s) available for lenalidomide and Disease Exacerbation

Article	Year
Lenalidomide in combination with R-CHOP produces high response rates and progression-free survival in new, untreated diffuse large B-cell lymphoma transformed from follicular lymphoma: results from the Phase 2 MC078E study. Blood cancer journal, 2021, 09-25, Volume: 11, Issue:9 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Disease Progression; Doxorubicin; Female; Humans; Lenalidomide; Lymphoma, Follicular; Lymphoma, Large B-Cell, Diffuse; Male; Middle Aged; Prednisone; Progression-Free Survival; Rituximab; Treatment Outcome; Vincristine; Young Adult	2021
Triplet Therapy, Transplantation, and Maintenance until Progression in Myeloma. The New England journal of medicine, 2022, 07-14, Volume: 387, Issue:2 Topics: Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Dexamethasone; Disease Progression; Disease-Free Survival; Humans; Lenalidomide; Maintenance Chemotherapy; Melphalan; Multiple Myeloma; Stem Cell Transplantation; Transplantation, Autologous	2022
Psychological distress among health care professionals of the three COVID-19 most affected Regions in Cameroon: Prevalence and associated factors. Annales medico-psychologiques, 2021, Volume: 179, Issue:2 Topics: 3' Untranslated Regions; 5'-Nucleotidase; A549 Cells; Accidental Falls; Acetylcholinesterase; Acrylic Resins; Actinobacillus; Acute Disease; Acute Kidney Injury; Adaptor Proteins, Signal Transducing; Adenosine; Adenosine Triphosphate; Administration, Inhalation; Administration, Oral; Adolescent; Adult; Advance Care Planning; Africa, Northern; Age Factors; Aged; Aged, 80 and over; Air Pollutants; Air Pollution; Air Pollution, Indoor; Albendazole; Aluminum Oxide; Anastomosis, Surgical; Ancylostoma; Ancylostomiasis; Androstadienes; Angiogenesis Inhibitors; Angiotensin II; Animals; Anti-Bacterial Agents; Anti-Infective Agents; Antibodies, Bispecific; Antibodies, Viral; Anticoagulants; Antihypertensive Agents; Antinematodal Agents; Antineoplastic Agents; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Antioxidants; Antiporters; Antiviral Agents; Apoptosis; Aptamers, Nucleotide; Aromatase Inhibitors; Asian People; Astrocytes; Atrial Fibrillation; Auditory Threshold; Aurora Kinase B; Australia; Autophagy; Autophagy-Related Protein 5; Autotrophic Processes; Bacillus cereus; Bacillus thuringiensis; Bacterial Proteins; Beclin-1; Belgium; Benzene; Benzene Derivatives; Benzhydryl Compounds; beta Catenin; beta-Arrestin 2; Biliary Tract Diseases; Biofilms; Biofuels; Biomarkers; Biomarkers, Tumor; Biomass; Biomechanical Phenomena; Bioreactors; Biosensing Techniques; Biosynthetic Pathways; Bismuth; Blood Platelets; Bone and Bones; Bone Regeneration; Bortezomib; Botulinum Toxins, Type A; Brain; Brain Injuries; Brain Ischemia; Brain Neoplasms; Breast Neoplasms; Breath Tests; Bronchodilator Agents; Calcium Phosphates; Cannabis; Carbon Dioxide; Carbon Isotopes; Carcinogenesis; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cardiac Resynchronization Therapy; Cardiac Resynchronization Therapy Devices; Cardiomyopathies; Cardiovascular Diseases; Cariostatic Agents; Case Managers; Case-Control Studies; Catalysis; Cation Transport Proteins; CD8-Positive T-Lymphocytes; Cecropia Plant; Cell Adhesion; Cell Count; Cell Differentiation; Cell Division; Cell Line; Cell Line, Tumor; Cell Membrane; Cell Movement; Cell Proliferation; Cell Self Renewal; Cell Survival; Cells, Cultured; Cellular Reprogramming; Cellulose; Charcoal; Chemical and Drug Induced Liver Injury; Chemical Phenomena; Chemokines; Chemoradiotherapy; Chemoreceptor Cells; Child; Child Abuse; Child, Preschool; China; Chlorogenic Acid; Chloroquine; Chromatography, Gas; Chronic Disease; Clinical Competence; Coated Materials, Biocompatible; Cochlea; Cohort Studies; Color; Comorbidity; Computer Simulation; Computer-Aided Design; Contraception; Contraceptive Agents, Female; Contrast Media; COP-Coated Vesicles; Coronavirus Infections; Cost of Illness; Coturnix; COVID-19; Creatinine; Cross-Over Studies; Cross-Sectional Studies; Culex; Curriculum; Cyclic N-Oxides; Cytokines; Cytoplasm; Cytotoxicity, Immunologic; Cytotoxins; Databases, Factual; Deep Learning; Delivery, Obstetric; Denitrification; Dental Caries; Denture, Complete; Dexamethasone; Diabetes Complications; Diabetes Mellitus; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Dielectric Spectroscopy; Diet, High-Fat; Dietary Fiber; Disease Models, Animal; Disease Progression; DNA; DNA Copy Number Variations; DNA, Mitochondrial; Dog Diseases; Dogs; Dopaminergic Neurons; Double-Blind Method; Down-Regulation; Doxorubicin; Drug Carriers; Drug Design; Drug Interactions; Drug Resistance, Bacterial; Drug Resistance, Neoplasm; Drug-Related Side Effects and Adverse Reactions; Drugs, Chinese Herbal; Dry Powder Inhalers; Dust; E2F1 Transcription Factor; Ecosystem; Education, Nursing; Education, Nursing, Baccalaureate; Electric Impedance; Electricity; Electrocardiography; Electrochemical Techniques; Electrochemistry; Electrodes; Electrophoresis, Polyacrylamide Gel; Endoplasmic Reticulum; Endothelial Cells; Environmental Monitoring; Enzyme Inhibitors; Epithelial Cells; Epithelial-Mesenchymal Transition; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Estrogen Receptor Modulators; Europe; Evoked Potentials, Auditory, Brain Stem; Exosomes; Feasibility Studies; Female; Ferricyanides; Ferrocyanides; Fibrinogen; Finite Element Analysis; Fistula; Fluorescent Dyes; Fluorides, Topical; Fluorodeoxyglucose F18; Fluticasone; Follow-Up Studies; Food Contamination; Food Microbiology; Foods, Specialized; Forensic Medicine; Frail Elderly; France; Free Radicals; Fresh Water; Fungi; Fungicides, Industrial; Galactosamine; Gastrointestinal Neoplasms; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Gene Frequency; Genetic Predisposition to Disease; Genotype; Gingival Hemorrhage; Glioblastoma; Glioma; Glomerular Filtration Rate; Glomerulosclerosis, Focal Segmental; Glucose; Glucose Transport Proteins, Facilitative; Glucosides; Glutamine; Glycolysis; Gold; GPI-Linked Proteins; Gram-Negative Bacteria; Gram-Positive Bacteria; Graphite; Haplotypes; HCT116 Cells; Healthy Volunteers; Hearing Loss; Heart Failure; Hedgehog Proteins; HEK293 Cells; HeLa Cells; Hemodynamics; Hemorrhage; Hepatocytes; Hippo Signaling Pathway; Histone Deacetylases; Homeostasis; Hospital Mortality; Hospitalization; Humans; Hydantoins; Hydrazines; Hydrogen Peroxide; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Hydroxylamines; Hypoglycemic Agents; Immunity, Innate; Immunoglobulin G; Immunohistochemistry; Immunologic Factors; Immunomodulation; Immunophenotyping; Immunotherapy; Incidence; Indazoles; Indonesia; Infant; Infant, Newborn; Infarction, Middle Cerebral Artery; Inflammation; Injections, Intramuscular; Insecticides; Insulin-Like Growth Factor I; Insurance, Health; Intention to Treat Analysis; Interleukin-1 Receptor-Associated Kinases; Interleukin-6; Intrauterine Devices; Intrauterine Devices, Copper; Iron; Ischemia; Jordan; Keratinocytes; Kidney; Kidney Diseases; Kir5.1 Channel; Klebsiella Infections; Klebsiella pneumoniae; Lab-On-A-Chip Devices; Laparoscopy; Lasers; Lasers, Semiconductor; Lenalidomide; Leptin; Lethal Dose 50; Levonorgestrel; Limit of Detection; Lipid Metabolism; Lipid Metabolism Disorders; Lipogenesis; Lipopolysaccharides; Liquid Biopsy; Liver; Liver Abscess, Pyogenic; Liver Cirrhosis; Liver Diseases; Liver Neoplasms; Longevity; Lung Neoplasms; Luteolin; Lymph Nodes; Lymphocyte Activation; Macaca fascicularis; Macrophages; Mad2 Proteins; Magnetic Resonance Imaging; Male; Mammary Glands, Human; Manganese; Manganese Compounds; MAP Kinase Signaling System; Materials Testing; Maternal Health Services; MCF-7 Cells; Medicaid; Medicine, Chinese Traditional; Melanoma; Membrane Proteins; Mental Health; Mercury; Metal Nanoparticles; Metals, Heavy; Metformin; Methionine Adenosyltransferase; Mice; Mice, Inbred BALB C; Mice, Inbred C3H; Mice, Inbred C57BL; Mice, Inbred CBA; Mice, Knockout; Mice, Nude; Microalgae; Microbial Sensitivity Tests; Microglia; MicroRNAs; Microscopy, Atomic Force; Microscopy, Electron, Scanning; Middle Aged; Mitochondria; Mitochondrial Proteins; Mitral Valve; Mitral Valve Insufficiency; Models, Anatomic; Molecular Structure; Molybdenum; Monocarboxylic Acid Transporters; Moths; MPTP Poisoning; Multigene Family; Multiparametric Magnetic Resonance Imaging; Multiple Myeloma; Muscle, Skeletal; Mutagens; Mutation; Myeloid Cells; Nanocomposites; Nanofibers; Nanomedicine; Nanoparticles; Nanowires; Neoadjuvant Therapy; Neomycin; Neoplasm Grading; Neoplasm Recurrence, Local; Neoplasms; Neoplastic Stem Cells; Neostriatum; Neovascularization, Pathologic; Netherlands; Neuromuscular Agents; Neurons; NF-E2-Related Factor 2; NF-kappa B; Nickel; Nitrogen Oxides; Non-alcoholic Fatty Liver Disease; Nucleosides; Nucleotidyltransferases; Nutritional Status; Obesity, Morbid; Ofloxacin; Oils, Volatile; Oligopeptides; Oncogene Protein v-akt; Optical Imaging; Organic Cation Transport Proteins; Organophosphonates; Osteoarthritis; Osteoarthritis, Hip; Osteoarthritis, Knee; Osteoblasts; Osteogenesis; Oxidation-Reduction; Oxidative Stress; Oxides; Oxygen Isotopes; Pancreas; Pancreaticoduodenectomy; Pandemics; Particle Size; Particulate Matter; Patient Acceptance of Health Care; Patient Compliance; PC-3 Cells; Peptide Fragments; Peptides; Periodontal Attachment Loss; Periodontal Index; Periodontal Pocket; Periodontitis; Peroxides; Peru; Pest Control, Biological; Phosphatidylinositol 3-Kinase; Phosphatidylinositol 3-Kinases; Phylogeny; Pilot Projects; Piperidines; Plant Bark; Plant Extracts; Plant Leaves; Plasmids; Platelet Function Tests; Pneumonia, Viral; Podocytes; Poly (ADP-Ribose) Polymerase-1; Poly(ADP-ribose) Polymerase Inhibitors; Polyethylene Terephthalates; Polymers; Polymorphism, Single Nucleotide; Porosity; Portugal; Positron-Emission Tomography; Postoperative Complications; Postural Balance; Potassium Channels, Inwardly Rectifying; Povidone; Powders; Precancerous Conditions; Precision Medicine; Predictive Value of Tests; Pregnancy; Prenatal Care; Prognosis; Promoter Regions, Genetic; Prospective Studies; Prostatectomy; Prostatic Neoplasms; Proteasome Inhibitors; Protective Agents; Protein Binding; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Protein Transport; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins c-akt; Psychiatric Nursing; PTEN Phosphohydrolase; Pulmonary Embolism; Pyrimethamine; Radiopharmaceuticals; Rats; Rats, Sprague-Dawley; Rats, Wistar; Reactive Oxygen Species; Receptor, ErbB-2; Receptor, IGF Type 1; Receptors, Estrogen; Receptors, G-Protein-Coupled; Recombinational DNA Repair; Recovery of Function; Regional Blood Flow; Renal Dialysis; Renin; Renin-Angiotensin System; Reperfusion Injury; Reproducibility of Results; Republic of Korea; Respiratory Distress Syndrome; Retrospective Studies; Rhodamines; Risk Assessment; Risk Factors; RNA, Long Noncoding; RNA, Messenger; Running; Saccharomyces cerevisiae; Saccharomyces cerevisiae Proteins; Salinity; Salmeterol Xinafoate; Sarcoma; Seasons; Shoulder Injuries; Signal Transduction; Silicon Dioxide; Silver; Sirtuin 1; Sirtuins; Skull Fractures; Social Determinants of Health; Sodium; Sodium Fluoride; Sodium Potassium Chloride Symporter Inhibitors; Sodium-Glucose Transporter 2 Inhibitors; Soil; Soil Pollutants; Spain; Spectrophotometry; Spectroscopy, Fourier Transform Infrared; Staphylococcal Protein A; Staphylococcus aureus; Stem Cells; Stereoisomerism; Stomach Neoplasms; Streptomyces; Strontium; Structure-Activity Relationship; Students, Nursing; Substance-Related Disorders; Succinic Acid; Sulfur; Surface Properties; Survival Rate; Survivin; Symporters; T-Lymphocytes; Temozolomide; Tensile Strength; Thiazoles; Thiobacillus; Thiohydantoins; Thiourea; Thrombectomy; Time Factors; Titanium; Tobacco Mosaic Virus; Tobacco Use Disorder; Toll-Like Receptor 4; Toluene; Tomography, X-Ray Computed; TOR Serine-Threonine Kinases; Toxicity Tests, Acute; Toxicity Tests, Subacute; Transcriptional Activation; Treatment Outcome; Troponin I; Tumor Cells, Cultured; Tumor Escape; Tumor Hypoxia; Tumor Microenvironment; Tumor Necrosis Factor Inhibitors; Tumor Necrosis Factor-alpha; Tyrosine; Ubiquitin-Protein Ligases; Ubiquitination; Ultrasonic Waves; United Kingdom; United States; United States Department of Veterans Affairs; Up-Regulation; Urea; Uric Acid; Urinary Bladder Neoplasms; Urinary Bladder, Neurogenic; Urine; Urodynamics; User-Computer Interface; Vemurafenib; Verbenaceae; Veterans; Veterans Health; Viral Load; Virtual Reality; Vitiligo; Water Pollutants, Chemical; Wildfires; Wnt Signaling Pathway; Wound Healing; X-Ray Diffraction; Xenograft Model Antitumor Assays; Xylenes; Young Adult; Zinc; Zinc Oxide; Zinc Sulfate; Zoonoses	2021
Continuous lenalidomide and low-dose dexamethasone in patients with transplant-ineligible newly diagnosed MM: FIRST trial subanalysis of Canadian/US patients. Cancer medicine, 2020, Volume: 9, Issue:23 Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Canada; Dexamethasone; Disease Progression; Drug Administration Schedule; Eligibility Determination; Female; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Male; Melphalan; Middle Aged; Multiple Myeloma; Prednisone; Progression-Free Survival; Thalidomide; Time Factors; United States	2020
A phase III study of lenalidomide maintenance after debulking therapy in patients with advanced cutaneous T-cell lymphoma - EORTC 21081 (NCT01098656): results and lessons learned for future trial designs. European journal of dermatology : EJD, 2017, Jun-01, Volume: 27, Issue:3 Topics: Aged; Angiogenesis Inhibitors; Cytoreduction Surgical Procedures; Disease Progression; Disease-Free Survival; Female; Humans; Lenalidomide; Lymphoma, T-Cell, Cutaneous; Male; Middle Aged; Neoplasm Staging; Skin Neoplasms; Thalidomide	2017
Clinical characteristics and outcomes according to age in lenalidomide-treated patients with RBC transfusion-dependent lower-risk MDS and del(5q). Journal of hematology & oncology, 2017, 06-26, Volume: 10, Issue:1 Topics: Adult; Age Factors; Aged; Aged, 80 and over; Chromosomes, Human, Pair 5; Cytogenetics; Disease Progression; Erythrocyte Transfusion; Female; Humans; Immunologic Factors; Lenalidomide; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Prognosis; Risk Factors; Thalidomide; Treatment Outcome	2017
Lenalidomide as second-line therapy for advanced hepatocellular carcinoma: exploration of biomarkers for treatment efficacy. Alimentary pharmacology & therapeutics, 2017, Volume: 46, Issue:8 Topics: Adult; Aged; alpha-Fetoproteins; Angiogenesis Inhibitors; Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Hepatocellular; Disease Progression; Disease-Free Survival; Female; Humans; Lenalidomide; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Sorafenib; Thalidomide; Treatment Outcome	2017
FDA Approval Summary: Daratumumab for Treatment of Multiple Myeloma After One Prior Therapy. The oncologist, 2017, Volume: 22, Issue:11 Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Dexamethasone; Disease Progression; Disease-Free Survival; Drug Approval; Drug Resistance, Neoplasm; Female; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Thalidomide; United States	2017
Lenalidomide maintenance after first-line therapy for high-risk chronic lymphocytic leukaemia (CLLM1): final results from a randomised, double-blind, phase 3 study. The Lancet. Haematology, 2017, Volume: 4, Issue:10 Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Disease Progression; Female; Humans; Lenalidomide; Leukemia, Lymphocytic, Chronic, B-Cell; Maintenance Chemotherapy; Male; Middle Aged; Neoplasm, Residual; Survival Analysis; Thalidomide; Treatment Outcome	2017
The European Medicines Agency Review of Carfilzomib for the Treatment of Adult Patients with Multiple Myeloma Who Have Received at Least One Prior Therapy. The oncologist, 2017, Volume: 22, Issue:11 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disease Progression; Disease-Free Survival; Drug-Related Side Effects and Adverse Reactions; Europe; Female; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Oligopeptides; Thalidomide	2017
Pharmacogenetic study of the impact of ABCB1 single-nucleotide polymorphisms on lenalidomide treatment outcomes in patients with multiple myeloma: results from a phase IV observational study and subsequent phase II clinical trial. Cancer chemotherapy and pharmacology, 2018, Volume: 81, Issue:1 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B; Disease Progression; Female; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Pharmacogenomic Testing; Polymorphism, Single Nucleotide; Prospective Studies; Skin Diseases; Treatment Outcome	2018
The Effect of Lenalidomide on Health-Related Quality of Life in Patients With Lower-Risk Non-del(5q) Myelodysplastic Syndromes: Results From the MDS-005 Study. Clinical lymphoma, myeloma & leukemia, 2018, Volume: 18, Issue:2 Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Chromosome Deletion; Chromosomes, Human, Pair 5; Disease Progression; Double-Blind Method; Female; Humans; Lenalidomide; Male; Middle Aged; Myelodysplastic Syndromes; Outcome Assessment, Health Care; Quality of Life; Risk Factors; Surveys and Questionnaires	2018
Lenalidomide treatment of myelodysplastic syndromes with chromosome 5q deletion: Results from the National Registry of the Italian Drug Agency. European journal of haematology, 2018, Volume: 101, Issue:1 Topics: Aged; Chromosome Deletion; Chromosomes, Human, Pair 5; Disease Progression; Female; Humans; Immunologic Factors; Italy; Karyotyping; Lenalidomide; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Prospective Studies; Registries; Remission Induction; Retrospective Studies; Thalidomide	2018
Lenalidomide as immune adjuvant to a dendritic cell vaccine in chronic lymphocytic leukemia patients. European journal of haematology, 2018, Volume: 101, Issue:1 Topics: Adjuvants, Immunologic; Adolescent; Adult; Aged; Aged, 80 and over; Anemia, Hemolytic, Autoimmune; Apoptosis; Cancer Vaccines; Combined Modality Therapy; Cyclophosphamide; Cytokines; Cytotoxicity, Immunologic; Dendritic Cells; Disease Progression; Female; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Injections, Intravenous; Injections, Subcutaneous; Lenalidomide; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Thalidomide; Thrombocytopenia; Transplantation, Autologous; Tumor Cells, Cultured; Vaccination	2018
Healthcare resource utilization with ixazomib or placebo plus lenalidomide-dexamethasone in the randomized, double-blind, phase 3 TOURMALINE-MM1 study in relapsed/refractory multiple myeloma. Journal of medical economics, 2018, Volume: 21, Issue:8 Topics: Absenteeism; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boron Compounds; Dexamethasone; Disease Progression; Double-Blind Method; Female; Glycine; Health Resources; Health Services; Hospitalization; Humans; Lenalidomide; Male; Middle Aged; Models, Econometric; Multiple Myeloma; Time Factors	2018
Elotuzumab plus lenalidomide and dexamethasone in relapsed/refractory multiple myeloma: Extended 4-year follow-up and analysis of relative progression-free survival from the randomized ELOQUENT-2 trial. Cancer, 2018, 10-15, Volume: 124, Issue:20 Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disease Progression; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Progression-Free Survival; Survival Analysis; Time Factors; Treatment Outcome	2018
Autologous Transplantation, Consolidation, and Maintenance Therapy in Multiple Myeloma: Results of the BMT CTN 0702 Trial. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2019, 03-01, Volume: 37, Issue:7 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Consolidation Chemotherapy; Dexamethasone; Disease Progression; Female; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Maintenance Chemotherapy; Male; Melphalan; Middle Aged; Multiple Myeloma; Myeloablative Agonists; Progression-Free Survival; Prospective Studies; Remission Induction; Reoperation; Time Factors; Transplantation, Autologous; United States; Young Adult	2019
Lenalidomide in International Prognostic Scoring System Low and Intermediate-1 risk myelodysplastic syndromes with del(5q): an Italian phase II trial of health-related quality of life, safety and efficacy. Leukemia & lymphoma, 2013, Volume: 54, Issue:11 Topics: Aged; Aged, 80 and over; Angiogenesis Inhibitors; Chromosome Deletion; Chromosomes, Human, Pair 5; Disease Progression; Female; Humans; Lenalidomide; Male; Middle Aged; Myelodysplastic Syndromes; Quality of Life; Thalidomide; Treatment Outcome	2013
Phase Ib dose-escalation study (PX-171-006) of carfilzomib, lenalidomide, and low-dose dexamethasone in relapsed or progressive multiple myeloma. Clinical cancer research : an official journal of the American Association for Cancer Research, 2013, Apr-15, Volume: 19, Issue:8 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Diarrhea; Disease Progression; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Fatigue; Female; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Neutropenia; Oligopeptides; Thalidomide; Treatment Outcome	2013
Oral lenalidomide with rituximab in relapsed or refractory diffuse large cell, follicular and transformed lymphoma: a phase II clinical trial. Leukemia, 2013, Volume: 27, Issue:9 Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Disease Progression; Female; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Lymphoma, Follicular; Lymphoma, Large B-Cell, Diffuse; Male; Middle Aged; Recurrence; Rituximab; Thalidomide; Tomography, X-Ray Computed; Treatment Outcome; Young Adult	2013
A phase 2, multicentre, single-arm, open-label study to evaluate the safety and efficacy of single-agent lenalidomide (Revlimid) in subjects with relapsed or refractory peripheral T-cell non-Hodgkin lymphoma: the EXPECT trial. European journal of cancer (Oxford, England : 1990), 2013, Volume: 49, Issue:13 Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Disease Progression; Disease-Free Survival; Drug Administration Schedule; Early Termination of Clinical Trials; Europe; Female; Humans; Immunologic Factors; Intention to Treat Analysis; Kaplan-Meier Estimate; Lenalidomide; Lymphoma, T-Cell, Peripheral; Male; Middle Aged; Thalidomide; Time Factors; Treatment Outcome	2013
Bortezomib induction, reduced-intensity transplantation, and lenalidomide consolidation-maintenance for myeloma: updated results. Blood, 2013, Aug-22, Volume: 122, Issue:8 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Disease Progression; Disease-Free Survival; Doxorubicin; Drug Administration Schedule; Female; Humans; Lenalidomide; Male; Melphalan; Middle Aged; Multiple Myeloma; Polyethylene Glycols; Pyrazines; Recurrence; Stem Cell Transplantation; Thalidomide; Transplantation, Autologous; Treatment Outcome	2013
A multicenter, open-label, phase 2 study of lenalidomide plus low-dose dexamethasone in Chinese patients with relapsed/refractory multiple myeloma: the MM-021 trial. Journal of hematology & oncology, 2013, Jun-19, Volume: 6 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; China; Dexamethasone; Disease Progression; Disease-Free Survival; Female; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Thalidomide; Treatment Outcome	2013
Lenalidomide plus dexamethasone for high-risk smoldering multiple myeloma. The New England journal of medicine, 2013, Aug-01, Volume: 369, Issue:5 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disease Progression; Female; Follow-Up Studies; Humans; Induction Chemotherapy; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Risk; Survival Rate; Thalidomide	2013
Single-agent lenalidomide in patients with mantle-cell lymphoma who relapsed or progressed after or were refractory to bortezomib: phase II MCL-001 (EMERGE) study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2013, Oct-10, Volume: 31, Issue:29 Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Agents; Boronic Acids; Bortezomib; Disease Progression; Female; Humans; Lenalidomide; Lymphoma, Mantle-Cell; Male; Middle Aged; Pyrazines; Recurrence; Thalidomide	2013
Phase 2 dose-expansion study (PX-171-006) of carfilzomib, lenalidomide, and low-dose dexamethasone in relapsed or progressive multiple myeloma. Blood, 2013, Oct-31, Volume: 122, Issue:18 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Diarrhea; Disease Progression; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Fatigue; Female; Humans; Kaplan-Meier Estimate; Lenalidomide; Lymphopenia; Male; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Neutropenia; Oligopeptides; Remission Induction; Thalidomide; Treatment Outcome	2013
Lenalidomide monotherapy in chemotherapy-naive, castration-resistant prostate cancer patients: final results of a phase II study. Clinical genitourinary cancer, 2014, Volume: 12, Issue:1 Topics: Aged; Aged, 80 and over; Angiogenesis Inhibitors; Disease Progression; Disease-Free Survival; Humans; Lenalidomide; Male; Middle Aged; Neoplasm Grading; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Quality of Life; Surveys and Questionnaires; Thalidomide; Treatment Outcome	2014
A prospective study of lenalidomide monotherapy for relapse after Allo-SCT for multiple myeloma. Bone marrow transplantation, 2014, Volume: 49, Issue:4 Topics: Adult; Aged; Angiogenesis Inhibitors; Disease Progression; Female; Hematopoietic Stem Cell Transplantation; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Prospective Studies; Remission Induction; Thalidomide; Transplantation Conditioning; Transplantation, Homologous	2014
Outcomes in RBC transfusion-dependent patients with Low-/Intermediate-1-risk myelodysplastic syndromes with isolated deletion 5q treated with lenalidomide: a subset analysis from the MDS-004 study. European journal of haematology, 2014, Volume: 93, Issue:5 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Chromosome Deletion; Chromosomes, Human, Pair 5; Cytogenetic Analysis; Disease Progression; Drug Administration Schedule; Erythrocyte Transfusion; Female; Humans; Lenalidomide; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Retrospective Studies; Risk; Survival Analysis; Thalidomide; Treatment Outcome	2014
A phase 2 single-center study of carfilzomib 56 mg/m2 with or without low-dose dexamethasone in relapsed multiple myeloma. Blood, 2014, Aug-07, Volume: 124, Issue:6 Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Disease Progression; Disease-Free Survival; Female; Humans; Kaplan-Meier Estimate; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Oligopeptides; Pyrazines; Risk Factors; Thalidomide; Treatment Outcome	2014
A phase II trial of lenalidomide, dexamethasone and cyclophosphamide for newly diagnosed patients with systemic immunoglobulin light chain amyloidosis. British journal of haematology, 2015, Volume: 170, Issue:6 Topics: Aged; Aged, 80 and over; Amyloidosis; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Dexamethasone; Disease Progression; Female; Humans; Immunoglobulin Light Chains; Lenalidomide; Male; Middle Aged; Survival Analysis; Thalidomide; Treatment Outcome	2015
Pomalidomide and Low-Dose Dexamethasone Improves Health-Related Quality of Life and Prolongs Time to Worsening in Relapsed/Refractory Patients With Multiple Myeloma Enrolled in the MM-003 Randomized Phase III Trial. Clinical lymphoma, myeloma & leukemia, 2015, Volume: 15, Issue:9 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Dexamethasone; Disease Progression; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Humans; Lenalidomide; Male; Multiple Myeloma; Neoplasm Recurrence, Local; Quality of Life; Thalidomide	2015
Randomized Trial of Lenalidomide Alone Versus Lenalidomide Plus Rituximab in Patients With Recurrent Follicular Lymphoma: CALGB 50401 (Alliance). Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2015, Nov-01, Volume: 33, Issue:31 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Aspirin; Disease Progression; Disease-Free Survival; Female; Heparin; Humans; Kaplan-Meier Estimate; Lenalidomide; Lymphoma, Follicular; Male; Middle Aged; Neoplasm Recurrence, Local; Risk Factors; Rituximab; Thalidomide; Thrombosis; Treatment Outcome	2015
Chemotherapy plus lenalidomide versus autologous transplantation, followed by lenalidomide plus prednisone versus lenalidomide maintenance, in patients with multiple myeloma: a randomised, multicentre, phase 3 trial. The Lancet. Oncology, 2015, Volume: 16, Issue:16 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Australia; Chemotherapy, Adjuvant; Cyclophosphamide; Czech Republic; Dexamethasone; Disease Progression; Disease-Free Survival; Female; Hematopoietic Stem Cell Transplantation; Humans; Italy; Kaplan-Meier Estimate; Lenalidomide; Maintenance Chemotherapy; Male; Melphalan; Middle Aged; Multiple Myeloma; Prednisone; Proportional Hazards Models; Risk Factors; Thalidomide; Time Factors; Transplantation, Autologous; Treatment Outcome	2015
Impact of renal impairment on outcomes with lenalidomide and dexamethasone treatment in the FIRST trial, a randomized, open-label phase 3 trial in transplant-ineligible patients with multiple myeloma. Haematologica, 2016, Volume: 101, Issue:3 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Creatinine; Dexamethasone; Disease Progression; Drug Administration Schedule; Female; Humans; Lenalidomide; Male; Melphalan; Middle Aged; Multiple Myeloma; Prednisone; Prognosis; Prospective Studies; Renal Insufficiency; Severity of Illness Index; Survival Analysis; Thalidomide; Treatment Outcome	2016
Phenotypic and genomic analysis of multiple myeloma minimal residual disease tumor cells: a new model to understand chemoresistance. Blood, 2016, Apr-14, Volume: 127, Issue:15 Topics: Aged; Bortezomib; Cell Adhesion Molecules; Dexamethasone; Disease Progression; Down-Regulation; Drug Resistance, Neoplasm; Female; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Genomics; Humans; Immunophenotyping; Integrins; Lenalidomide; Male; Melphalan; Models, Genetic; Multiple Myeloma; Neoplasm, Residual; Phenotype; Plasma Cells; Prednisone; Prognosis; Thalidomide	2016
Siltuximab (CNTO 328) with lenalidomide, bortezomib and dexamethasone in newly-diagnosed, previously untreated multiple myeloma: an open-label phase I trial. Blood cancer journal, 2016, Feb-12, Volume: 6 Topics: Aged; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Chromosome Aberrations; Dexamethasone; Disease Progression; Female; Humans; Lenalidomide; Male; Maximum Tolerated Dose; Middle Aged; Multiple Myeloma; Neoplasm Staging; Quality of Life; Thalidomide; Treatment Outcome	2016
Bendamustine + rituximab chemoimmunotherapy and maintenance lenalidomide in relapsed, refractory chronic lymphocytic leukaemia and small lymphocytic lymphoma: A Wisconsin Oncology Network Study. British journal of haematology, 2016, Volume: 173, Issue:2 Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Disease Progression; Disease-Free Survival; Female; Humans; Lenalidomide; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Recurrence; Remission Induction; Rituximab; Thalidomide; Treatment Outcome	2016
Lenalidomide and low-dose dexamethasone in Japanese patients with newly diagnosed multiple myeloma: A phase II study. Cancer science, 2016, Volume: 107, Issue:5 Topics: Aged; Aged, 80 and over; Dexamethasone; Disease Progression; Female; Humans; Japan; Kaplan-Meier Estimate; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Survival Analysis; Thalidomide	2016
Updated Outcomes and Impact of Age With Lenalidomide and Low-Dose Dexamethasone or Melphalan, Prednisone, and Thalidomide in the Randomized, Phase III FIRST Trial. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2016, 10-20, Volume: 34, Issue:30 Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disease Progression; Disease-Free Survival; Female; Humans; Lenalidomide; Male; Melphalan; Middle Aged; Multiple Myeloma; Neoplasm Staging; Prednisone; Survival Rate; Thalidomide	2016
Bendamustine, Low-dose dexamethasone, and lenalidomide (BdL) for the treatment of patients with relapsed/refractory multiple myeloma confirms very promising results in a phase I/II study. Leukemia & lymphoma, 2017, Volume: 58, Issue:3 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Biomarkers; Dexamethasone; Disease Progression; Drug Resistance, Neoplasm; Female; Humans; Lenalidomide; Male; Maximum Tolerated Dose; Middle Aged; Multiple Myeloma; Neoplasm Staging; Recurrence; Retreatment; Survival Analysis; Thalidomide; Treatment Outcome	2017
Multicenter Phase II Study of Lenalidomide in Relapsed or Recurrent Adult T-Cell Leukemia/Lymphoma: ATLL-002. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2016, Volume: 34, Issue:34 Topics: Administration, Oral; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Disease Progression; Endpoint Determination; Female; Humans; Lenalidomide; Leukemia-Lymphoma, Adult T-Cell; Male; Middle Aged; Prognosis; Recurrence; Remission Induction; Survival Rate; Thalidomide; Treatment Outcome	2016
Continuous treatment with lenalidomide and low-dose dexamethasone in transplant-ineligible patients with newly diagnosed multiple myeloma in Asia: subanalysis of the FIRST trial. British journal of haematology, 2017, Volume: 176, Issue:5 Topics: Adult; Aged; Aged, 80 and over; Anemia; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Asia; Asian People; Dexamethasone; Disease Progression; Disease-Free Survival; Female; Humans; Infections; Lenalidomide; Male; Melphalan; Middle Aged; Multiple Myeloma; Neutropenia; Prednisone; Remission Induction; Thalidomide; Treatment Outcome	2017
Upfront lower dose lenalidomide is less toxic and does not compromise efficacy for vulnerable patients with relapsed refractory multiple myeloma: final analysis of the phase II RevLite study. British journal of haematology, 2017, Volume: 177, Issue:3 Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disease Progression; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Prognosis; Prospective Studies; Recurrence; Thalidomide	2017
Lenalidomide therapy for metastatic renal cell carcinoma. American journal of clinical oncology, 2008, Volume: 31, Issue:3 Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Disease Progression; Disease-Free Survival; Fatigue; Female; Hematologic Diseases; Humans; Kidney Neoplasms; Lenalidomide; Male; Middle Aged; Survival Rate; Thalidomide	2008
Lenalidomide alone or in combination with dexamethasone is highly effective in patients with relapsed multiple myeloma following allogeneic stem cell transplantation and increases the frequency of CD4+Foxp3+ T cells. Leukemia, 2009, Volume: 23, Issue:3 Topics: Adjuvants, Immunologic; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disease Progression; Disease-Free Survival; Female; Forkhead Transcription Factors; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Lymphocyte Count; Male; Middle Aged; Multiple Myeloma; Salvage Therapy; T-Lymphocytes, Regulatory; Thalidomide; Transplantation, Homologous; Treatment Outcome	2009
Lenalidomide in combination with dexamethasone for the treatment of multiple myeloma after one prior therapy. The oncologist, 2008, Volume: 13, Issue:10 Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disease Progression; Double-Blind Method; Drug Approval; Female; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Placebos; Thalidomide; United States; United States Food and Drug Administration	2008
Lenalidomide, adriamycin, and dexamethasone (RAD) in patients with relapsed and refractory multiple myeloma: a report from the German Myeloma Study Group DSMM (Deutsche Studiengruppe Multiples Myelom). Blood, 2009, Apr-30, Volume: 113, Issue:18 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disease Progression; Doxorubicin; Drug Resistance, Neoplasm; Female; Humans; Lenalidomide; Male; Maximum Tolerated Dose; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Neoplasm Staging; Prognosis; Salvage Therapy; Survival Rate; Thalidomide; Time Factors; Treatment Outcome	2009
Safety and efficacy of single-agent lenalidomide in patients with relapsed and refractory multiple myeloma. Blood, 2009, Jul-23, Volume: 114, Issue:4 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Disease Progression; Drug Dosage Calculations; Drug Resistance, Neoplasm; Female; Humans; Lenalidomide; Male; Middle Aged; Models, Biological; Multiple Myeloma; Recurrence; Survival Analysis; Thalidomide; Treatment Outcome	2009
Results of a multicenter, randomized, double-blind phase 2/3 study of lenalidomide in the treatment of pretreated relapsed or refractory metastatic malignant melanoma. Cancer, 2010, Jan-01, Volume: 116, Issue:1 Topics: Antineoplastic Agents; Disease Progression; Double-Blind Method; Drug Resistance, Neoplasm; Female; Humans; Lenalidomide; Male; Melanoma; Middle Aged; Neoplasm Metastasis; Recurrence; Retreatment; Skin Neoplasms; Thalidomide	2010
Lenalidomide, melphalan, prednisone and thalidomide (RMPT) for relapsed/refractory multiple myeloma. Leukemia, 2010, Volume: 24, Issue:5 Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Disease Progression; Drug Resistance, Neoplasm; Female; Humans; Lenalidomide; Male; Melphalan; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Prednisone; Remission Induction; Salvage Therapy; Survival Rate; Thalidomide; Treatment Outcome	2010
Lenalidomide in nonmetastatic biochemically relapsed prostate cancer: results of a phase I/II double-blinded, randomized study. Clinical cancer research : an official journal of the American Association for Cancer Research, 2010, Nov-01, Volume: 16, Issue:21 Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Agents; Biomarkers, Tumor; Disease Progression; Double-Blind Method; Humans; Lenalidomide; Male; Middle Aged; Prostate-Specific Antigen; Prostatic Neoplasms; Recurrence; Testosterone; Thalidomide	2010
Effects of lenalidomide and dexamethasone treatment duration on survival in patients with relapsed or refractory multiple myeloma treated with lenalidomide and dexamethasone. Clinical lymphoma, myeloma & leukemia, 2011, Volume: 11, Issue:1 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disease Progression; Drug Administration Schedule; Female; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Survival Analysis; Thalidomide; Treatment Outcome	2011
Lenalidomide, cyclophosphamide and dexamethasone (CRd) for newly diagnosed multiple myeloma: results from a phase 2 trial. American journal of hematology, 2011, Volume: 86, Issue:8 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Dexamethasone; Disease Progression; Female; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Myeloma Proteins; Neutropenia; Patient Dropouts; Survival Analysis; Thalidomide	2011
Lenalidomide modulates IL-8 and anti-prostate antibody levels in men with biochemically recurrent prostate cancer. The Prostate, 2012, Volume: 72, Issue:5 Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antigens, Surface; Antineoplastic Agents; Biomarkers, Tumor; Disease Progression; Humans; Immunomodulation; Interleukin-8; Lenalidomide; Male; Middle Aged; Neoplasm Recurrence, Local; Prostate-Specific Antigen; Prostatectomy; Prostatic Neoplasms; Radiotherapy, Adjuvant; Retrospective Studies; Thalidomide	2012
Efficacy, safety and quality-of-life associated with lenalidomide plus dexamethasone for the treatment of relapsed or refractory multiple myeloma: the Spanish experience. Leukemia & lymphoma, 2012, Volume: 53, Issue:9 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disease Progression; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Neutropenia; Quality of Life; Recurrence; Spain; Surveys and Questionnaires; Thalidomide; Thrombocytopenia; Time Factors; Treatment Outcome	2012
Elotuzumab in combination with lenalidomide and low-dose dexamethasone in relapsed or refractory multiple myeloma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2012, Jun-01, Volume: 30, Issue:16 Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disease Progression; Drug Administration Schedule; Humans; Lenalidomide; Middle Aged; Multiple Myeloma; Recurrence; Thalidomide	2012
Postallograft lenalidomide induces strong NK cell-mediated antimyeloma activity and risk for T cell-mediated GvHD: Results from a phase I/II dose-finding study. Experimental hematology, 2013, Volume: 41, Issue:2 Topics: Adult; Aged; Combined Modality Therapy; Disease Progression; Dose-Response Relationship, Immunologic; Female; Graft vs Host Disease; Graft vs Tumor Effect; Humans; Immunologic Factors; Killer Cells, Natural; Lenalidomide; Lymphocyte Activation; Lymphocyte Count; Maintenance Chemotherapy; Male; Middle Aged; Multiple Myeloma; Peripheral Blood Stem Cell Transplantation; Prospective Studies; Remission Induction; T-Lymphocyte Subsets; T-Lymphocytes, Regulatory; Thalidomide; Transplantation Conditioning; Transplantation, Homologous	2013
Melphalan, lenalidomide and dexamethasone for the treatment of immunoglobulin light chain amyloidosis: results of a phase II trial. Haematologica, 2013, Volume: 98, Issue:5 Topics: Aged; Aged, 80 and over; Amyloidosis; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disease Progression; Female; Humans; Immunoglobulin Light Chains; Lenalidomide; Male; Melphalan; Middle Aged; Thalidomide; Treatment Outcome	2013
The activity of lenalidomide with or without dexamethasone in patients with primary systemic amyloidosis. Blood, 2007, Jan-15, Volume: 109, Issue:2 Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Amyloidosis; Dexamethasone; Disease Progression; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Immunoglobulin Light Chains; Lenalidomide; Male; Middle Aged; Predictive Value of Tests; Survival Rate; Thalidomide; Treatment Outcome	2007
Pharmacokinetics of lenalidomide in subjects with various degrees of renal impairment and in subjects on hemodialysis. Journal of clinical pharmacology, 2007, Volume: 47, Issue:12 Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents; Area Under Curve; Disease Progression; Dose-Response Relationship, Drug; Female; Half-Life; Humans; Kidney; Kidney Failure, Chronic; Lenalidomide; Male; Metabolic Clearance Rate; Middle Aged; Renal Dialysis; Severity of Illness Index; Stereoisomerism; Tandem Mass Spectrometry; Thalidomide	2007
Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma. The New England journal of medicine, 2007, Nov-22, Volume: 357, Issue:21 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disease Progression; Drug Therapy, Combination; Female; Glucocorticoids; Humans; Immunologic Factors; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Recurrence; Survival Analysis; Thalidomide	2007
Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America. The New England journal of medicine, 2007, Nov-22, Volume: 357, Issue:21 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disease Progression; Double-Blind Method; Female; Glucocorticoids; Humans; Immunologic Factors; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Recurrence; Survival Analysis; Thalidomide	2007
Combined pegylated liposomal doxorubicin and bortezomib is highly effective in patients with recurrent or refractory multiple myeloma who received prior thalidomide/lenalidomide therapy. Cancer, 2008, Apr-01, Volume: 112, Issue:7 Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Disease Progression; Doxorubicin; Female; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Polyethylene Glycols; Pyrazines; Salvage Therapy; Survival Rate; Thalidomide	2008

Other Studies

93 other study(ies) available for lenalidomide and Disease Exacerbation

Article	Year
Incidence and Predictors of Community-Acquired Pneumonia in Patients With Hematological Cancers Between 2016 and 2019. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2022, 09-29, Volume: 75, Issue:6 Topics: Adult; Anti-Bacterial Agents; Case-Control Studies; Cohort Studies; Community-Acquired Infections; Disease Progression; Female; Hematologic Neoplasms; Hospitalization; Humans; Incidence; Lenalidomide; Male; Methotrexate; Pneumonia; Pneumonia, Pneumococcal; Rituximab; Thalidomide	2022
Real-world patient characteristics and treatment outcomes among nontransplanted multiple myeloma patients who received Bortezomib in combination with Lenalidomide and Dexamethasone as first line of therapy in the United States. BMC cancer, 2022, Aug-18, Volume: 22, Issue:1 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Dexamethasone; Disease Progression; Humans; Lenalidomide; Multiple Myeloma; Retrospective Studies; Treatment Outcome; United States	2022
Immune biomarkers of response to immunotherapy in patients with high-risk smoldering myeloma. Cancer cell, 2022, 11-14, Volume: 40, Issue:11 Topics: Biomarkers; Clinical Trials, Phase II as Topic; Disease Progression; Humans; Immunologic Factors; Immunotherapy; Lenalidomide; Multiple Myeloma; Smoldering Multiple Myeloma	2022
Gain of Chromosome 1q is associated with early progression in multiple myeloma patients treated with lenalidomide, bortezomib, and dexamethasone. Blood cancer journal, 2019, 11-25, Volume: 9, Issue:12 Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Chromosome Duplication; Chromosomes, Human, Pair 1; Dexamethasone; Disease Progression; DNA Copy Number Variations; Female; Genetic Association Studies; Genetic Predisposition to Disease; Humans; Kaplan-Meier Estimate; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Prognosis; Proportional Hazards Models; Treatment Outcome	2019
Elevated eosinophil level predicted long time to next treatment in relapsed or refractory myeloma patients treated with lenalidomide. Cancer medicine, 2020, Volume: 9, Issue:5 Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Disease Progression; Drug Resistance, Neoplasm; Eosinophils; Female; Follow-Up Studies; Humans; Lenalidomide; Leukocyte Count; Male; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Predictive Value of Tests; Prognosis; Retrospective Studies; Time Factors; Time-to-Treatment	2020
[Treatment of early relapsed plasma cells leukemia after unrelated bone marrow transplant with KRD (carfilzomib, lenalidomide and dexamethasone): a case report.] Recenti progressi in medicina, 2020, Volume: 111, Issue:3 Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Dexamethasone; Disease Progression; Fatal Outcome; Humans; Lenalidomide; Leukemia, Plasma Cell; Male; Middle Aged; Oligopeptides; Plasma Cells; Recurrence	2020
Treatment of Smoldering Myeloma: Problems With Study Design as well as Biological and Clinical Implications. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2020, 04-20, Volume: 38, Issue:12 Topics: Biological Products; Disease Progression; Humans; Lenalidomide; Multiple Myeloma; Smoldering Multiple Myeloma	2020
An Unusual Cause of a Pathological Vertebral Fracture: Solitary Plasmacytoma. The American journal of the medical sciences, 2020, Volume: 360, Issue:2 Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Decompression, Surgical; Dexamethasone; Disease Progression; Female; Fractures, Compression; Fractures, Spontaneous; Humans; Humeral Fractures; Immunoglobulin A; Immunoglobulin G; Immunoglobulin M; Laminectomy; Lenalidomide; Multiple Myeloma; Plasmacytoma; Positron-Emission Tomography; Spinal Cord Compression; Spinal Fractures; Spinal Neoplasms; Thoracic Vertebrae; Tomography, X-Ray Computed	2020
Outcome of COVID-19 in multiple myeloma patients in relation to treatment. European journal of haematology, 2020, Volume: 105, Issue:6 Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Betacoronavirus; Cohort Studies; Coronavirus Infections; COVID-19; Dexamethasone; Disease Progression; Female; Humans; Immunomodulation; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Pandemics; Pneumonia, Viral; Prognosis; Remission Induction; SARS-CoV-2; Severity of Illness Index; Survival Analysis; Thalidomide; Treatment Outcome	2020
Outcome of lower-risk myelodysplastic syndrome with ring sideroblasts (MDS-RS) after failure of erythropoiesis- stimulating agents. Leukemia research, 2020, Volume: 99 Topics: Activin Receptors, Type II; Aged; Anemia, Sideroblastic; Azacitidine; Disease Progression; Erythrocyte Transfusion; Erythropoietin; Female; Ferritins; Follow-Up Studies; Hematinics; Humans; Immunoglobulin Fc Fragments; Kaplan-Meier Estimate; Lenalidomide; Male; Proportional Hazards Models; Recombinant Fusion Proteins; Salvage Therapy; Treatment Failure	2020
Persistent challenges with treating multiple myeloma early. Blood, 2021, 01-28, Volume: 137, Issue:4 Topics: Antineoplastic Combined Chemotherapy Protocols; Asymptomatic Diseases; Cost of Illness; Dexamethasone; Disease Progression; Early Detection of Cancer; Humans; Immunoglobulin Light Chains; Immunologic Factors; Lenalidomide; Multiple Myeloma; Myeloma Proteins; Protease Inhibitors; Quality of Life; Randomized Controlled Trials as Topic; Risk Assessment; Smoldering Multiple Myeloma; Time-to-Treatment	2021
Original Versus Generic Lenalidomide in Patients with Relapsed/Refractory Multiple Myeloma: Comparison of Efficacy and Adverse Events Turkish journal of haematology : official journal of Turkish Society of Haematology, 2021, 02-25, Volume: 38, Issue:1 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Disease Progression; Drug Resistance, Neoplasm; Drugs, Generic; Female; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Neoplasm Grading; Neoplasm Staging; Odds Ratio; Recurrence; Retreatment; Treatment Outcome	2021
Treatment pathways and disease journeys differ before and after introduction of novel agents in newly diagnosed multiple myeloma in Taiwan. Scientific reports, 2021, 01-13, Volume: 11, Issue:1 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Combined Modality Therapy; Disease Progression; Female; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Progression-Free Survival; Retrospective Studies; Taiwan; Thalidomide; Transplantation, Autologous; Treatment Outcome	2021
Impact of PPM1D mutations in patients with myelodysplastic syndrome and deletion of chromosome 5q. American journal of hematology, 2021, 06-01, Volume: 96, Issue:6 Topics: Abnormal Karyotype; Adult; Aged; Aged, 80 and over; Alleles; Anemia, Macrocytic; Chromosome Deletion; Chromosomes, Human, Pair 5; Clonal Evolution; Disease Progression; Drug Resistance, Neoplasm; Female; Genes, p53; Humans; Lenalidomide; Male; Middle Aged; Mutation; Myelodysplastic Syndromes; Protein Phosphatase 2C; Retrospective Studies	2021
Outcome of Lower-Risk Patients With Myelodysplastic Syndromes Without 5q Deletion After Failure of Erythropoiesis-Stimulating Agents. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2017, May-10, Volume: 35, Issue:14 Topics: Aged; Aged, 80 and over; Anemia; Antilymphocyte Serum; Antineoplastic Agents; Arsenic; Azacitidine; Chromosome Deletion; Chromosomes, Human, Pair 5; Cyclosporine; Cytarabine; Decitabine; Disease Progression; Enzyme Inhibitors; Erythrocyte Transfusion; Female; Hematinics; Humans; Hydroxyurea; Immunologic Factors; Lenalidomide; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Recurrence; Retreatment; Retrospective Studies; Risk Factors; Survival Rate; Thalidomide; Treatment Failure; Tretinoin; Valproic Acid	2017
Results from Two Consecutive Studies of Consolidation Therapy after Autologous Transplant for Multiple Myeloma: Thalidomide, Dexamethasone, and Clarithromycin or Lenalidomide, Dexamethasone, and Clarithromycin. Acta haematologica, 2017, Volume: 137, Issue:3 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Clarithromycin; Combined Modality Therapy; Consolidation Chemotherapy; Dexamethasone; Disease Progression; Female; Hematopoietic Stem Cell Transplantation; Humans; Immunologic Factors; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Neoplasms, Second Primary; Peripheral Nervous System Diseases; Thalidomide; Transplantation, Autologous; Treatment Outcome	2017
Clonal evolution in myelodysplastic syndromes. Nature communications, 2017, 04-21, Volume: 8 Topics: Aged; Angiogenesis Inhibitors; Biomarkers, Tumor; Bone Marrow Cells; Clonal Evolution; Disease Management; Disease Progression; Drug Resistance, Neoplasm; Exome Sequencing; Female; Follow-Up Studies; Gene Expression Regulation, Neoplastic; GTP Phosphohydrolases; Humans; Lenalidomide; Male; Membrane Proteins; Middle Aged; Monitoring, Physiologic; Mutation; Myelodysplastic Syndromes; Proto-Oncogene Proteins p21(ras); Thalidomide; Tumor Suppressor Protein p53	2017
Anti-CD138 chimeric antigen receptor-modified T cell therapy for multiple myeloma with extensive extramedullary involvement. Annals of hematology, 2017, Volume: 96, Issue:8 Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Bortezomib; Combined Modality Therapy; Disease Progression; Fatal Outcome; Hematopoietic Stem Cell Transplantation; Humans; Immunotherapy, Adoptive; Lenalidomide; Leukemia, Plasma Cell; Male; Middle Aged; Molecular Targeted Therapy; Multiple Myeloma; Pneumonia; Recombinant Fusion Proteins; Recurrence; Salvage Therapy; Syndecan-1; Thalidomide; Transplantation, Autologous	2017
[A prospective multi-center trial of non-interventional and observational study of lenalidomide in Chinese patients with multiple myeloma]. Zhonghua nei ke za zhi, 2017, Jul-01, Volume: 56, Issue:7 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chromosome Aberrations; Dexamethasone; Disease Progression; Disease-Free Survival; Drug-Related Side Effects and Adverse Reactions; Female; Humans; In Situ Hybridization, Fluorescence; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Neutropenia; Prospective Studies; Remission Induction; Survival Rate; Thalidomide; Treatment Outcome	2017
JAM-A overexpression is related to disease progression in diffuse large B-cell lymphoma and downregulated by lenalidomide. Scientific reports, 2017, 08-07, Volume: 7, Issue:1 Topics: Animals; Cell Adhesion Molecules; Cell Line, Tumor; Disease Progression; Epithelial-Mesenchymal Transition; Female; Gene Expression Regulation, Neoplastic; Humans; Lenalidomide; Lymphatic Metastasis; Lymphoma, Large B-Cell, Diffuse; Male; Mice; Neoplasm Invasiveness; Nodal Protein; Prognosis; Receptors, Cell Surface; Signal Transduction; Transforming Growth Factor beta; Up-Regulation; Xenograft Model Antitumor Assays; Zebrafish	2017
Observational study of lenalidomide in patients with mantle cell lymphoma who relapsed/progressed after or were refractory/intolerant to ibrutinib (MCL-004). Journal of hematology & oncology, 2017, 11-02, Volume: 10, Issue:1 Topics: Adenine; Aged; Aged, 80 and over; Disease Progression; Female; Humans; Lenalidomide; Lymphoma, Mantle-Cell; Male; Middle Aged; Piperidines; Pyrazoles; Pyrimidines; Recurrence; Thalidomide	2017
Emergence and evolution of Haematologica, 2018, Volume: 103, Issue:4 Topics: Chromosome Deletion; Chromosomes, Human, Pair 5; Disease Progression; Female; Humans; Lenalidomide; Male; Middle Aged; Mutation; Myelodysplastic Syndromes; Prognosis; Tumor Suppressor Protein p53	2018
Healthcare resource utilization among patients with relapsed multiple myeloma in the UK, France, and Italy. Journal of medical economics, 2018, Volume: 21, Issue:5 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Disease Progression; Female; France; Health Expenditures; Health Resources; Hospitalization; Humans; Italy; Lenalidomide; Male; Middle Aged; Models, Econometric; Multiple Myeloma; Retrospective Studies; Thalidomide; United Kingdom	2018
Lenalidomide plus dexamethasone for patients with relapsed or refractory multiple myeloma: Final results of a non-interventional study and comparison with the pivotal phase 3 clinical trials. Leukemia research, 2018, Volume: 68 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase III as Topic; Dexamethasone; Disease Progression; Febrile Neutropenia; Female; Humans; Infections; Kaplan-Meier Estimate; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Renal Insufficiency; Thrombosis	2018
Cost-effectiveness of lenalidomide in combination with dexamethasone compared to bortezomib in combination with dexamethasone for the second-line treatment of multiple myeloma in Chile. Medwave, 2018, Jun-29, Volume: 18, Issue:3 Topics: Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Chile; Cost-Benefit Analysis; Dexamethasone; Disease Progression; Female; Humans; Lenalidomide; Male; Markov Chains; Middle Aged; Multiple Myeloma; Quality-Adjusted Life Years; Retrospective Studies	2018
Treatment Outcomes and Health Care Resource Utilization in Patients With Newly Diagnosed Multiple Myeloma Receiving Lenalidomide-only Maintenance, Any Maintenance, or No Maintenance: Results from the Connect MM Registry. Clinical therapeutics, 2018, Volume: 40, Issue:7 Topics: Adult; Aged; Disease Progression; Female; Health Resources; Hematopoietic Stem Cell Transplantation; Humans; Immunologic Factors; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Registries; Transplantation, Autologous; Treatment Outcome; Young Adult	2018
Novel EZH2 mutation in a patient with secondary B-cell acute lymphocytic leukemia after deletion 5q myelodysplastic syndrome treated with lenalidomide: A case report. Medicine, 2019, Volume: 98, Issue:1 Topics: Aged; Anemia; Angiogenesis Inhibitors; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Hormonal; B-Lymphocytes; Bone Marrow; Chromosome Deletion; Cyclophosphamide; Dexamethasone; Disease Progression; Enhancer of Zeste Homolog 2 Protein; Humans; Lenalidomide; Male; Mutation; Myelodysplastic Syndromes; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Thrombocytopenia; Treatment Outcome	2019
A case of double-refractory multiple myeloma with both the IgH-MMSET fusion protein and the congenital abnormality t(11;22). International journal of hematology, 2019, Volume: 109, Issue:6 Topics: Aged; Bortezomib; Chromosome Aberrations; Chromosomes, Human, Pair 11; Chromosomes, Human, Pair 14; Chromosomes, Human, Pair 22; Chromosomes, Human, Pair 4; Disease Progression; Drug Therapy, Combination; Fatal Outcome; Female; Humans; Lenalidomide; Multiple Myeloma; Oncogene Proteins, Fusion	2019
Clinical efficacy of bortezomib and lenalidomide in blastic plasmacytoid dendritic cell neoplasm. Annals of hematology, 2019, Volume: 98, Issue:6 Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Bees; Bone Marrow; Bortezomib; Dendritic Cells; Disease Progression; Drug Resistance, Neoplasm; Forearm Injuries; Histiocytic Disorders, Malignant; Humans; Insect Bites and Stings; Lenalidomide; Male; Middle Aged; Neoplasm Proteins; NF-kappa B; Salvage Therapy	2019
Addition of Cyclophosphamide "On Demand" to Lenalidomide and Corticosteroids in Patients With Relapsed/Refractory Multiple Myeloma-A Retrospective Review of a Single-center Experience. Clinical lymphoma, myeloma & leukemia, 2019, Volume: 19, Issue:4 Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Dexamethasone; Disease Progression; Drug Resistance, Neoplasm; Female; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Progression-Free Survival; Recurrence; Retrospective Studies; Treatment Outcome	2019
Treatment of patients with multiple myeloma progressing on frontline-therapy with lenalidomide. Blood cancer journal, 2019, 03-20, Volume: 9, Issue:4 Topics: Angiogenesis Inhibitors; Disease Progression; Humans; Lenalidomide; Multiple Myeloma	2019
Response to First Cycle Is the Major Predictor of Long-Term Response to Lenalidomide and Dexamethasone Therapy in Relapsed and Refractory Multiple Myeloma: Can We Spare Patients the Toxicity and Costs of Additional Agents? Clinical lymphoma, myeloma & leukemia, 2019, Volume: 19, Issue:9 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Dexamethasone; Disease Management; Disease Progression; Drug Resistance, Neoplasm; Female; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Neoplasm Staging; Prognosis; Registries; Survival Analysis; Treatment Outcome; Young Adult	2019
Pulmonary toxicity after long-term treatment with lenalidomide in two myeloma patients. European respiratory review : an official journal of the European Respiratory Society, 2013, Mar-01, Volume: 22, Issue:127 Topics: Aged, 80 and over; Angiogenesis Inhibitors; Disease Progression; Drug Administration Schedule; Fatal Outcome; Female; Humans; Iatrogenic Disease; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Pneumonia; Thalidomide; Time Factors; Tomography, X-Ray Computed	2013
Response to lenalidomide in myelodysplastic syndromes with del(5q): influence of cytogenetics and mutations. British journal of haematology, 2013, Volume: 162, Issue:1 Topics: Aged; Aged, 80 and over; Chromosome Banding; Chromosome Deletion; Chromosomes, Human, Pair 5; Disease Progression; Female; Humans; Immunologic Factors; In Situ Hybridization, Fluorescence; Lenalidomide; Male; Middle Aged; Mutation; Myelodysplastic Syndromes; Polymorphism, Single Nucleotide; Thalidomide; Treatment Outcome	2013
Therapeutic effects of lenalidomide on hemorrhagic intestinal myeloma-associated AL amyloidosis. Internal medicine (Tokyo, Japan), 2013, Volume: 52, Issue:10 Topics: Aged; Amyloid; Amyloidosis; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Blood Transfusion; Bone Diseases; Boronic Acids; Bortezomib; Carpal Tunnel Syndrome; Dexamethasone; Disease Progression; Doxorubicin; Duodenal Diseases; Female; Femur Head; Fractures, Spontaneous; Gastrointestinal Hemorrhage; Hip Fractures; Humans; Jejunal Diseases; Lenalidomide; Melphalan; Multiple Myeloma; Osteolysis; Prednisolone; Pyrazines; Thalidomide; Vincristine	2013
Correlation between burden of 17P13.1 alteration and rapid escape to plasma cell leukaemia in multiple myeloma. British journal of haematology, 2013, Volume: 162, Issue:4 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Chromosomes, Human, Pair 13; Chromosomes, Human, Pair 17; Dexamethasone; Disease Progression; Female; Genes, p53; Humans; In Situ Hybridization, Fluorescence; Lenalidomide; Leukemia, Plasma Cell; Male; Melphalan; Multiple Myeloma; Prednisone; Pyrazines; Sequence Deletion; Thalidomide; Treatment Outcome; Trisomy	2013
Single-agent lenalidomide is active in patients with relapsed or refractory aggressive non-Hodgkin lymphoma who received prior stem cell transplantation. British journal of haematology, 2013, Volume: 162, Issue:5 Topics: Adult; Aged; Angiogenesis Inhibitors; Combined Modality Therapy; Disease Progression; Drug Evaluation; Female; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Lymphoma, Non-Hodgkin; Male; Middle Aged; Recurrence; Retrospective Studies; Thalidomide; Treatment Outcome; Young Adult	2013
Combination of intravenous immunoglobulins and lenalidomide in the treatment of scleromyxedema. Journal of the American Academy of Dermatology, 2013, Volume: 69, Issue:2 Topics: Administration, Oral; Adult; Biopsy, Needle; Disease Progression; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Follow-Up Studies; Humans; Immunoglobulins, Intravenous; Immunohistochemistry; Lenalidomide; Male; Scleromyxedema; Severity of Illness Index; Thalidomide; Treatment Outcome	2013
Efficacy and safety profile of long-term exposure to lenalidomide in patients with recurrent multiple myeloma. Cancer, 2013, Oct-15, Volume: 119, Issue:20 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disease Progression; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Neoplasm Staging; Prognosis; Retrospective Studies; Salvage Therapy; Survival Rate; Thalidomide	2013
Extended survival and reduced risk of AML progression in erythroid-responsive lenalidomide-treated patients with lower-risk del(5q) MDS. Leukemia, 2014, Volume: 28, Issue:5 Topics: Aged; Chromosome Deletion; Disease Progression; Erythrocyte Transfusion; Female; Humans; Lenalidomide; Leukemia, Myeloid, Acute; Male; Myelodysplastic Syndromes; Survival Analysis; Thalidomide	2014
Long-term disease control in patients with newly diagnosed multiple myeloma after suspension of lenalidomide therapy. American journal of hematology, 2014, Volume: 89, Issue:3 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disease Progression; Disease-Free Survival; Drug Administration Schedule; Female; Humans; Kaplan-Meier Estimate; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Remission Induction; Retrospective Studies; Salvage Therapy; Thalidomide; Treatment Outcome; Withholding Treatment	2014
Transfusion dependence development and disease evolution in patients with MDS and del(5q) and without transfusion needs at diagnosis. Leukemia research, 2014, Volume: 38, Issue:3 Topics: Adult; Aged; Aged, 80 and over; Anemia; Antineoplastic Agents; Biomarkers, Tumor; Blood Transfusion; Chromosome Deletion; Chromosomes, Human, Pair 5; Disease Progression; Female; Humans; Lenalidomide; Male; Middle Aged; Multivariate Analysis; Myelodysplastic Syndromes; Prognosis; Retrospective Studies; Survival Analysis; Thalidomide; Time Factors	2014
The difficulty to define progression patterns in patients with early stage myelodysplastic syndromes and deletion 5q--new prognostic markers are needed. Leukemia research, 2014, Volume: 38, Issue:3 Topics: Antineoplastic Agents; Biomarkers, Tumor; Blood Transfusion; Chromosome Deletion; Chromosomes, Human, Pair 5; Disease Progression; Humans; Lenalidomide; Myelodysplastic Syndromes; Prognosis; Survival Analysis; Thalidomide	2014
Multivariate time-dependent comparison of the impact of lenalidomide in lower-risk myelodysplastic syndromes with chromosome 5q deletion. British journal of haematology, 2014, Volume: 166, Issue:2 Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Chromosome Deletion; Chromosomes, Human, Pair 5; Disease Progression; Drug Evaluation; Erythrocyte Transfusion; Female; Follow-Up Studies; Humans; Kaplan-Meier Estimate; Lenalidomide; Male; Middle Aged; Multivariate Analysis; Myelodysplastic Syndromes; Prognosis; Retrospective Studies; Thalidomide; Treatment Outcome	2014
[CME myelodysplasia - a frequent hematologic neoplasia in the elderly]. Praxis, 2014, May-21, Volume: 103, Issue:11 Topics: Aged, 80 and over; Anemia, Aplastic; Azacitidine; Bone Marrow; Bone Marrow Examination; Cell Proliferation; Cell Transformation, Neoplastic; Decitabine; Diagnosis, Differential; Disease Progression; Hematopoiesis; Humans; Lenalidomide; Leukemia, Myeloid, Acute; Male; Myelodysplastic Syndromes; Prognosis; Thalidomide	2014
Lenalidomide in relapsed and refractory multiple myeloma disease: feasibility and benefits of long-term treatment. Annals of hematology, 2014, Volume: 93, Issue:12 Topics: Adult; Aged; Aged, 80 and over; Allografts; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Chromosome Aberrations; Dexamethasone; Disease Progression; Drug Evaluation; Feasibility Studies; Female; Hematologic Diseases; Hematopoietic Stem Cell Transplantation; Humans; Kaplan-Meier Estimate; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Pyrazines; Recurrence; Retrospective Studies; Salvage Therapy; Sensation Disorders; Thalidomide; Thromboembolism; Transplantation, Autologous	2014
Vemurafenib response in 2 patients with posttransplant refractory BRAF V600E-mutated multiple myeloma. Clinical lymphoma, myeloma & leukemia, 2014, Volume: 14, Issue:5 Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Carcinoma, Squamous Cell; Combined Modality Therapy; Dexamethasone; Disease Progression; Fatal Outcome; Hematopoietic Stem Cell Transplantation; Humans; Indoles; Lenalidomide; Male; Mediastinal Neoplasms; Middle Aged; Multiple Myeloma; Mutation, Missense; Neoplasm Proteins; Neoplasms, Second Primary; Osteolysis; Palliative Care; Plasmacytoma; Point Mutation; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; Pyrazines; Remission Induction; Salvage Therapy; Sulfonamides; Thalidomide; Transplantation, Autologous; Treatment Outcome; Vemurafenib	2014
Report of 6 cases of large granular lymphocytic leukemia and plasma cell dyscrasia. Clinical lymphoma, myeloma & leukemia, 2014, Volume: 14, Issue:5 Topics: Aged; Aged, 80 and over; Anemia; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Causality; Cladribine; Combined Modality Therapy; Cyclophosphamide; Disease Progression; Female; Humans; Lenalidomide; Leukemia, Large Granular Lymphocytic; Male; Melphalan; Methotrexate; Middle Aged; Multiple Myeloma; Neutropenia; Paraproteinemias; Peripheral Blood Stem Cell Transplantation; Prednisone; Protease Inhibitors; Pyrazines; Registries; Retrospective Studies; Thalidomide	2014
Renal thrombotic microangiopathy and podocytopathy associated with the use of carfilzomib in a patient with multiple myeloma. BMC nephrology, 2014, Sep-30, Volume: 15 Topics: Acute Kidney Injury; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Combined Modality Therapy; Cyclophosphamide; Dexamethasone; Disease Progression; Edema; Fatal Outcome; Hematopoietic Stem Cell Transplantation; Humans; Hypertension, Renal; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Oligopeptides; Podocytes; Proteasome Inhibitors; Proteinuria; Pyrazines; Recurrence; Shock, Septic; Teniposide; Thalidomide; Thrombotic Microangiopathies	2014
Impact of disease status on outcome in relapsed and refractory multiple myeloma treated with lenalidomide. Leukemia & lymphoma, 2015, Volume: 56, Issue:8 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Disease Progression; Female; Follow-Up Studies; Humans; Immunologic Factors; Kaplan-Meier Estimate; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Recurrence; Thalidomide; Treatment Outcome	2015
Patterns of total cost and economic consequences of progression for patients with newly diagnosed multiple myeloma. Current medical research and opinion, 2015, Volume: 31, Issue:6 Topics: Adult; Aged; Bortezomib; Costs and Cost Analysis; Disease Progression; Female; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Retrospective Studies; Thalidomide	2015
Lenalidomide in patients with red blood cell transfusion-dependent myelodysplastic syndrome and del(5q): a single-centre "real-world" experience. Leukemia & lymphoma, 2015, Volume: 56, Issue:11 Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Bone Marrow; Chromosome Deletion; Chromosomes, Human, Pair 5; Comorbidity; Disease Progression; Erythrocyte Transfusion; Female; Follow-Up Studies; Gene Expression; Humans; Lenalidomide; Leukemia, Myeloid, Acute; Male; Middle Aged; Mutation; Myelodysplastic Syndromes; Prognosis; Thalidomide; Treatment Outcome; Tumor Suppressor Protein p53	2015
Development of acquired hemophilia A during treatment of multiple myeloma with lenalidomide. [Rinsho ketsueki] The Japanese journal of clinical hematology, 2015, Volume: 56, Issue:5 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Disease Progression; Female; Hemophilia A; Humans; Lenalidomide; Multiple Myeloma; Thalidomide	2015
Bortezomib produces high hematological response rates with prolonged renal survival in monoclonal immunoglobulin deposition disease. Kidney international, 2015, Volume: 88, Issue:5 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Cyclophosphamide; Dexamethasone; Disease Progression; Female; Follow-Up Studies; Glomerular Basement Membrane; Glomerular Filtration Rate; Humans; Immunoglobulin Heavy Chains; Immunoglobulin Light Chains; Kidney Diseases; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Proteinuria; Retrospective Studies; Survival Rate; Thalidomide; Waldenstrom Macroglobulinemia	2015
Dose-adjusted Lenalidomide Combined with Low-dose Dexamethasone Rescues Older Patients with Bortezomib-resistant Multiple Myeloma. Internal medicine (Tokyo, Japan), 2015, Volume: 54, Issue:14 Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Dexamethasone; Disease Progression; Female; Follow-Up Studies; Humans; Lenalidomide; Male; Multiple Myeloma; Thalidomide; Treatment Outcome	2015
Ruxolitinib Treatment in a Patient with Primary Myelofibrosis Resistant to Conventional Therapies and Splenectomy: A Case Report. Turkish journal of haematology : official journal of Turkish Society of Haematology, 2015, Volume: 32, Issue:2 Topics: Aged; Aspergillosis; Blood Transfusion; Danazol; Disease Progression; Drug Resistance; Fatal Outcome; Humans; Hydroxyurea; Janus Kinase 2; Lenalidomide; Leukemia, Myeloid, Acute; Male; Nitriles; Primary Myelofibrosis; Protein Kinase Inhibitors; Pyrazoles; Pyrimidines; Splenectomy; Splenic Infarction; Thalidomide	2015
Treatment of Patients With Myelodysplastic Syndrome With Lenalidomide in Clinical Routine in Austria. Clinical lymphoma, myeloma & leukemia, 2015, Volume: 15, Issue:11 Topics: Adult; Aged; Aged, 80 and over; Anemia, Macrocytic; Angiogenesis Inhibitors; Austria; Chromosome Aberrations; Chromosome Deletion; Chromosomes, Human, Pair 5; Comorbidity; Disease Progression; Erythrocyte Transfusion; Female; Humans; Immunologic Factors; Lenalidomide; Male; Middle Aged; Myelodysplastic Syndromes; Retrospective Studies; Standard of Care; Survival Analysis; Thalidomide; Treatment Outcome	2015
TLR4/TIRAP polymorphisms are associated with progression and survival of patients with symptomatic myeloma. British journal of haematology, 2016, Volume: 172, Issue:1 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Disease Progression; DNA, Neoplasm; Female; Germ-Line Mutation; Humans; Lenalidomide; Male; Membrane Glycoproteins; Middle Aged; Multiple Myeloma; Neoplasm Proteins; Polymorphism, Single Nucleotide; Prognosis; Receptors, Interleukin-1; Survival Analysis; Thalidomide; Toll-Like Receptor 4	2016
Efficacy and safety of lenalidomide treatment in multiple myeloma (MM) patients--Report of the Polish Myeloma Group. Leukemia research, 2016, Volume: 40 Topics: Adult; Aged; Aged, 80 and over; Disease Progression; Female; Humans; Immunologic Factors; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Thalidomide	2016
Choosing a systemic treatment for advanced stage cutaneous T-cell lymphoma: mycosis fungoides and Sézary syndrome. Hematology. American Society of Hematology. Education Program, 2015, Volume: 2015 Topics: Alemtuzumab; Aminopterin; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Clinical Trials as Topic; Deoxycytidine; Depsipeptides; Diphtheria Toxin; Disease Progression; Doxorubicin; Electrons; Gemcitabine; Humans; Hydroxamic Acids; Immunotherapy; Incidence; Interleukin-2; Lenalidomide; Lymphoma, T-Cell; Mycosis Fungoides; Pentostatin; Photopheresis; Polyethylene Glycols; Randomized Controlled Trials as Topic; Recombinant Fusion Proteins; Retinoids; Sezary Syndrome; Stem Cell Transplantation; Thalidomide; United States; Vorinostat	2015
Autoimmune diseases and myelodysplastic syndromes. American journal of hematology, 2016, Volume: 91, Issue:5 Topics: Adult; Aged; Aged, 80 and over; Autoimmune Diseases; Azacitidine; Comorbidity; Disease Progression; Disease Susceptibility; Female; Follow-Up Studies; Hashimoto Disease; Humans; Immunocompromised Host; Immunosuppressive Agents; Kaplan-Meier Estimate; Lenalidomide; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Prevalence; Proportional Hazards Models; Retrospective Studies; Thalidomide; Thyroiditis, Autoimmune; Young Adult	2016
Subsequent primary malignancies and acute myelogenous leukemia transformation among myelodysplastic syndrome patients treated with or without lenalidomide. Cancer medicine, 2016, Volume: 5, Issue:7 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Case-Control Studies; Cell Transformation, Neoplastic; Cohort Studies; Disease Progression; Female; Follow-Up Studies; Humans; Lenalidomide; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Neoplasms, Second Primary; Registries; Retrospective Studies; Risk Factors; Thalidomide	2016
Rapidly Progressive Polyneuropathy in a Patient With Monoclonal Gammopathy: A Case Report of POEMS Syndrome and Beyond. Medicine, 2016, Volume: 95, Issue:16 Topics: Adult; Diagnosis, Differential; Disease Progression; Genetic Markers; Genetic Testing; Hematopoietic Stem Cell Transplantation; Humans; Immunologic Factors; Lenalidomide; Male; POEMS Syndrome; Thalidomide	2016
Potential role of exosome-associated microRNA panels and in vivo environment to predict drug resistance for patients with multiple myeloma. Oncotarget, 2016, May-24, Volume: 7, Issue:21 Topics: Antineoplastic Agents; Biomarkers, Tumor; Bortezomib; C-Reactive Protein; Chromosome Aberrations; Chromosomes, Human, Pair 1; Disease Progression; Down-Regulation; Drug Resistance, Neoplasm; Exosomes; Female; Gene Amplification; Humans; Immunoglobulin Light Chains; Lenalidomide; Male; Microarray Analysis; MicroRNAs; Middle Aged; Multiple Myeloma; Predictive Value of Tests; Risk Factors; Thalidomide; Tumor Microenvironment	2016
Circulating immune cell phenotype can predict the outcome of lenalidomide plus low-dose dexamethasone treatment in patients with refractory/relapsed multiple myeloma. Cancer immunology, immunotherapy : CII, 2016, Volume: 65, Issue:8 Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Dexamethasone; Disease Progression; Female; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Phenotype; Thalidomide	2016
Minimal residual disease after transplantation or lenalidomide-based consolidation in myeloma patients: a prospective analysis. Oncotarget, 2017, Jan-24, Volume: 8, Issue:4 Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Consolidation Chemotherapy; Disease Progression; Female; Humans; Lenalidomide; Maintenance Chemotherapy; Male; Middle Aged; Multiple Myeloma; Neoplasm, Residual; Prospective Studies; Thalidomide; Transplantation, Autologous; Treatment Outcome	2017
Progression in patients with low- and intermediate-1-risk del(5q) myelodysplastic syndromes is predicted by a limited subset of mutations. Haematologica, 2017, Volume: 102, Issue:3 Topics: Aged; Aged, 80 and over; Biomarkers; Chromosome Deletion; Chromosomes, Human, Pair 5; Computational Biology; Disease Progression; Female; Gene Expression; Gene Expression Profiling; Hematopoietic Stem Cells; Humans; Lenalidomide; Male; Mesenchymal Stem Cells; Middle Aged; Mutation; Myelodysplastic Syndromes; Prognosis; Stem Cell Niche; Thalidomide; Treatment Outcome	2017
Role of serum free light chain assay in the detection of early relapse and prediction of prognosis after relapse in multiple myeloma patients treated upfront with novel agents. Haematologica, 2017, Volume: 102, Issue:3 Topics: Antineoplastic Agents; Biomarkers, Tumor; Bortezomib; Disease Progression; Gene Expression; Humans; Immunoglobulin Light Chains; Immunoglobulin M; Immunoglobulins; Lenalidomide; Multiple Myeloma; Prognosis; Recurrence; Stem Cell Transplantation; Survival Analysis; Thalidomide	2017
Outcome of patients treated for myelodysplastic syndromes without deletion 5q after failure of lenalidomide therapy. Oncotarget, 2017, Jun-06, Volume: 8, Issue:23 Topics: Adult; Aged; Aged, 80 and over; Anemia; Angiogenesis Inhibitors; Chromosome Deletion; Chromosomes, Human, Pair 5; Disease Progression; Female; Humans; Lenalidomide; Middle Aged; Myelodysplastic Syndromes; Prognosis; Survival Analysis; Thalidomide; Treatment Outcome; Young Adult	2017
E(mu)-TCL1 mice represent a model for immunotherapeutic reversal of chronic lymphocytic leukemia-induced T-cell dysfunction. Proceedings of the National Academy of Sciences of the United States of America, 2009, Apr-14, Volume: 106, Issue:15 Topics: Animals; Disease Models, Animal; Disease Progression; Gene Expression Profiling; Humans; Immunological Synapses; Immunotherapy; Lenalidomide; Leukemia, Lymphocytic, Chronic, B-Cell; Mice; Mice, Transgenic; Proto-Oncogene Proteins; Signal Transduction; T-Lymphocytes; Thalidomide	2009
Clonal heterogeneity in the 5q- syndrome: p53 expressing progenitors prevail during lenalidomide treatment and expand at disease progression. Haematologica, 2009, Volume: 94, Issue:12 Topics: Aged; Antineoplastic Agents; Bone Marrow Cells; Chromosome Banding; Chromosome Deletion; Chromosomes, Human, Pair 5; Clone Cells; Disease Progression; Female; Gene Expression Profiling; Genetic Heterogeneity; Humans; In Situ Hybridization, Fluorescence; Karyotyping; Lenalidomide; Mutation; Myelodysplastic Syndromes; Thalidomide; Tumor Suppressor Protein p53	2009
Patients with del(5q) MDS who fail to achieve sustained erythroid or cytogenetic remission after treatment with lenalidomide have an increased risk for clonal evolution and AML progression. Annals of hematology, 2010, Volume: 89, Issue:4 Topics: Adult; Aged; Aged, 80 and over; Chromosome Deletion; Chromosomes, Human, Pair 5; Disease Progression; Erythroid Cells; Female; Follow-Up Studies; Humans; Karyotyping; Lenalidomide; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Remission Induction; Risk Factors; Thalidomide; Treatment Failure	2010
Treatment of multiple myeloma: 2009 update. Prescrire international, 2009, Volume: 18, Issue:104 Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Disease Progression; Doxorubicin; Humans; Lenalidomide; Melphalan; Multiple Myeloma; Prednisone; Pyrazines; Stem Cell Transplantation; Thalidomide; Transplantation, Autologous; Treatment Outcome; Vincristine	2009
Analysis of efficacy and prognostic factors of lenalidomide treatment as part of a Dutch compassionate use program. Clinical lymphoma, myeloma & leukemia, 2010, Volume: 10, Issue:2 Topics: Adult; Aged; Aged, 80 and over; Boronic Acids; Bortezomib; Clinical Trials as Topic; Compassionate Use Trials; Dexamethasone; Disease Progression; Female; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Pyrazines; Recurrence; Research; Stem Cell Transplantation; Thalidomide	2010
Lenalidomide in combination with dexamethasone: effective regimen in patients with relapsed or refractory multiple myeloma complicated by renal impairment. Annals of hematology, 2011, Volume: 90, Issue:4 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase III as Topic; Dexamethasone; Disease Progression; Drug Therapy, Combination; Female; Humans; Kaplan-Meier Estimate; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Renal Insufficiency; Retrospective Studies; Thalidomide; Treatment Outcome	2011
Lenalidomide: an update on evidence from clinical trials. Blood reviews, 2010, Volume: 24 Suppl 1 Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Dexamethasone; Disease Progression; Disease-Free Survival; Drug Administration Schedule; Granulocyte Colony-Stimulating Factor; Humans; Immunologic Factors; Lenalidomide; Multiple Myeloma; Recurrence; Thalidomide; Treatment Outcome	2010
Polycythemia vera evolving into a rapidly progressive Ph-negative del(5q)-positive myeloproliferative neoplasm refractory to lenalidomide. Leukemia research, 2011, Volume: 35, Issue:5 Topics: Aged; Antineoplastic Agents; Chromosome Deletion; Chromosomes, Human, Pair 5; Disease Progression; Drug Resistance, Neoplasm; Female; Humans; Lenalidomide; Myeloproliferative Disorders; Neoplasms; Philadelphia Chromosome; Polycythemia Vera; Splenomegaly; Thalidomide	2011
Myelodysplastic syndrome presenting as generalized granulomatous dermatitis. Archives of dermatology, 2011, Volume: 147, Issue:3 Topics: Aged; Antineoplastic Agents; Biopsy; Blood Cell Count; Dermatitis; Disease Progression; Granuloma; Humans; Lenalidomide; Male; Myelodysplastic Syndromes; Pruritus; Thalidomide; Time Factors	2011
Impact of lenalidomide dose on progression-free survival in patients with relapsed or refractory multiple myeloma. Leukemia, 2011, Volume: 25, Issue:10 Topics: Antineoplastic Agents; Dexamethasone; Disease Progression; Dose-Response Relationship, Drug; Humans; Lenalidomide; Multiple Myeloma; Recurrence; Regression Analysis; Survival Analysis; Thalidomide	2011
Telomere shortening, clonal evolution and disease progression in myelodysplastic syndrome patients with 5q deletion treated with lenalidomide. Leukemia, 2012, Volume: 26, Issue:2 Topics: Antineoplastic Agents; Chromosome Deletion; Chromosomes, Human, Pair 5; Disease Progression; Humans; Lenalidomide; Myelodysplastic Syndromes; Telomere; Thalidomide	2012
Treatment with lenalidomide does not appear to increase the risk of progression in lower risk myelodysplastic syndromes with 5q deletion. A comparative analysis by the Groupe Francophone des Myelodysplasies. Haematologica, 2012, Volume: 97, Issue:2 Topics: Adult; Aged; Aged, 80 and over; Chromosome Deletion; Chromosomes, Human, Pair 5; Cohort Studies; Disease Progression; Female; France; Humans; Lenalidomide; Male; Middle Aged; Myelodysplastic Syndromes; Survival Rate; Thalidomide; Treatment Outcome	2012
Efficacy of lenalidomide plus dexamethasone in patients older than 75 years with relapsed multiple myeloma. Leukemia & lymphoma, 2012, Volume: 53, Issue:7 Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disease Progression; Disease-Free Survival; Drug Administration Schedule; Female; Humans; Lenalidomide; Male; Multiple Myeloma; Recurrence; Retrospective Studies; Thalidomide; Treatment Outcome	2012
Lenalidomide in combination with dexamethasone improves survival and time-to-progression in patients ≥65 years old with relapsed or refractory multiple myeloma. International journal of hematology, 2012, Volume: 96, Issue:2 Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disease Progression; Female; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Neoplasm Staging; Recurrence; Risk Factors; Thalidomide; Treatment Outcome	2012
Lenalidomide (Revlimid), bortezomib (Velcade) and dexamethasone for heavily pretreated relapsed or refractory multiple myeloma. Leukemia & lymphoma, 2013, Volume: 54, Issue:3 Topics: Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Disease Progression; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Humans; Kaplan-Meier Estimate; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Muscle Weakness; Neutropenia; Pneumonia; Pyrazines; Recurrence; Retrospective Studies; Thalidomide; Treatment Outcome	2013
Improving the outlook for myelodysplastic syndrome. Journal of the National Cancer Institute, 2012, Aug-22, Volume: 104, Issue:16 Topics: Antimetabolites, Antineoplastic; Azacitidine; Biomarkers, Tumor; Decitabine; Disease Progression; DNA Methylation; Enzyme Inhibitors; Epigenesis, Genetic; Humans; Lenalidomide; Leukemia, Myeloid, Acute; Methyltransferases; Molecular Targeted Therapy; Myelodysplastic Syndromes; Phosphoproteins; Point Mutation; Prognosis; Ribonucleoprotein, U2 Small Nuclear; Risk Assessment; RNA Splicing; RNA Splicing Factors; Spliceosomes; Thalidomide	2012
Lenalidomide does not increase AML progression risk in RBC transfusion-dependent patients with Low- or Intermediate-1-risk MDS with del(5q): a comparative analysis. Leukemia, 2013, Volume: 27, Issue:5 Topics: Adult; Aged; Aged, 80 and over; Chromosome Deletion; Chromosomes, Human, Pair 5; Disease Progression; Erythrocyte Transfusion; Female; Humans; Lenalidomide; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Proportional Hazards Models; Retrospective Studies; Risk; Thalidomide	2013
Multiple myeloma, version 1.2013. Journal of the National Comprehensive Cancer Network : JNCCN, 2013, Jan-01, Volume: 11, Issue:1 Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Boronic Acids; Bortezomib; Dexamethasone; Disease Progression; Humans; Hydroxamic Acids; Lenalidomide; Multiple Myeloma; Nitrogen Mustard Compounds; Oligopeptides; Peripheral Nervous System Diseases; Practice Guidelines as Topic; Pyrazines; Recurrence; Salvage Therapy; Thalidomide; Vorinostat	2013
Novel immunomodulatory therapies in the treatment of multiple myeloma. Oncology (Williston Park, N.Y.), 2004, Volume: 18, Issue:8 Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Disease Progression; Female; Humans; Immunosuppressive Agents; Immunotherapy; Lenalidomide; Multiple Myeloma; Thalidomide	2004
New drugs for multiple myeloma. Clinical advances in hematology & oncology : H&O, 2006, Volume: 4, Issue:8 Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Disease Progression; Drug Design; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Multiple Myeloma; Pyrazines; Survival Rate; Thalidomide; Treatment Outcome	2006
48th annual meeting of the American Society of Hematology December 9-12, 2006, Orlando, FL. Clinical lymphoma & myeloma, 2007, Volume: 7, Issue:4 Topics: Administration, Oral; Animals; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Disease Progression; Drug Therapy, Combination; Hematologic Diseases; Hematology; Humans; Lenalidomide; Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Melphalan; Multiple Myeloma; Prednisone; Pyrazines; Quinolones; Recurrence; Stem Cell Transplantation; Thalidomide; Transplantation Conditioning; Transplantation, Autologous	2007
Spinal epidural lipomatosis in myeloma. Leukemia & lymphoma, 2007, Volume: 48, Issue:10 Topics: Adrenal Cortex Hormones; Antineoplastic Agents; Dexamethasone; Disease Progression; Humans; Lenalidomide; Lipomatosis; Magnetic Resonance Imaging; Male; Middle Aged; Multiple Myeloma; Spinal Cord; Spinal Diseases; Thalidomide; Treatment Outcome	2007
Long-term results of response to therapy, time to progression, and survival with lenalidomide plus dexamethasone in newly diagnosed myeloma. Mayo Clinic proceedings, 2007, Volume: 82, Issue:10 Topics: Adolescent; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disease Progression; Disease-Free Survival; Drug Administration Schedule; Female; Humans; Lenalidomide; Male; Multiple Myeloma; Stem Cell Transplantation; Survival Rate; Thalidomide	2007
Azotemia associated with use of lenalidomide in plasma cell dyscrasias. Leukemia & lymphoma, 2008, Volume: 49, Issue:6 Topics: Acute Kidney Injury; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Azotemia; Dexamethasone; Disease Progression; Female; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Paraproteinemias; Paraproteins; Renal Dialysis; Thalidomide	2008